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ABSTRACT 
Insulin resistance and/or B cell secretory defect have been accepted as the fundamental 
features in the pathogenes is of type 2 diabetes mellitus, though the exact molecular 
defect affecting the insulin secretion or sensitivity still to be clearly elucidated. The 
present study was undertaken to determine CAPN 10 gene SNP-44 T>C polymorphism 
in Bangladesh type 2 diabetes mellitus and explore its relationship with its insulin 
secretory capacity and insulin sensitivity. A total number of 65 T2DM subjects were 
recruited and 91 subjects served as control. Glucose was measured by glucose-oxidase, 
lipids by enzymatic-colorimatric, insulin by ELI SA methods. Homeostatic model 
assessment was used to calculate pancreatic B cell secretion, expressed on HOMA %B 
and insulin sensitivity, HOMA%S . DNA was extracted using QIAGEN spin column 
blood DNA kit. CAPN 10 gene polymorphic marker was determined by mutation 
specific PCR. Data were managed by stati stical package for social science (SPSS). P<O.5 
was taken as level significance. T2DM and Control subjects were age and BMI matched. 
Fasting serum insulin (flU/ml , mean±SD) in the T2DM subjects was significantly higher 
compared to controls (7.97±3.83 vs 5.01 ±0.57). Insulin secretory capacity (HOMA%B) 
in the T2DM group and the controls did not show any significant difference (p=0.240). 
Insulin sensitivi ty (I-IOMA%S) was significantly lower in the T2DM group compared to 
the controls (48.9±2 1.7 vs 79.9±20.5) (p<O.OOI). CAPNJO gene SNP-44 genotype 
li"cquencies for the T2DM were 0.662, 0.323 and 0.150 for Wild, Ht and Hz variant 
respectively and in the controls the frequencies were 0.670, 0.297 and 0.330 respectively, 
which did not show any significant association with diabetes mellitus. Subjects with 
variant (TC and IT) genotype did not show significant difference regarding glucose, 
BMI, I-IOMA%B, HOMA%S either in the T2DM or cOntrol group. In conclusion (i) 
CAPN 10 SNP 44 T>C polymorphism was not associated with T2DM of Bangladeshi 
onglll . (ii) Insulin sensitivity appeared to be predominant in the subsets of T2DM 
subjects, and (iii) CAPN 10 SNP 44 T>C variant did not show any relation with 
pancreatic B cell secretion and insulin sensitivity of the study subjects. 
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INTRODUCTION 
INTRODUCTION 
Diabetes Mell itus (DM) is chronic metabolic disorders mainly characterized by high rise 
in blood sugar levels, affecting multiple organ systems (WHO, 1999). This condition 
may ari se mainly due to impairment of insulin action, insulin secretion or both (ADA, 
2005). The World Health Organization (WHO) sponsored estimate, showed in 1995 that 
there were 135 million diabetic individuals and projected the number to increase around 
300 mill ion by the year 2025 (King el aI. , 1998). Subsequent study estimated the global 
prevalence of diabetes fo r all age-groups to ri se from 2.8% in 2000 to 4.4% in 2030 and 
also demonstrated the total number of diabetics to rise from 171 million in 2000 to 366 
million in 2030. It was also shown that about two third of the rise in total diabetic 
patients would be constituted from those of the developing countries particularl y China, 
India, Indo nesia, Pakistan and Bangladesh (Wild el ai. , 2004). Based on recent 
community based study, prevalence of diabetes in Bangladesh was fo und to be about 7%. 
St udies involving rural and urban population revealed the prevalence of diabetes 4% and 
I 1.4% respectively (Sayeed el aI. , 2007). 
Class ification of Diabetes Mellitus 
Classification of diabetic patients has been a difficult"task. In earl y days it used to be 
classi fi ed onl y the basis of age of onset and need for insulin of the individual to control 
blood glucose. In early 50 's two major types of diabetes was introduced - Type I 
Diabe tes Mellitus (T IDM) and Type 2 Diabetes Mellitus (T2 DM) (Lawrence, 195 1). 
However, this did not solve the variations showed by the diabeti cs over the years of 
diagnosis. Thus in late 70's National Institute of Health (NIH) and United States of 
America (USA) collecti vely introduced National Diabetes Data Group for formulation of 
class ification and diagnos is of diabetes (NDDG, 1979). Subsequently there have been 
major revisions in diagnosti c cri teria and classification of diabetes by committees from 
both ADA and WH O (WHO 1985 and 1999; ADA 1997). The present diabetes 
c1assiticat ion, originall y proposed by ADA (1997) and later endorsed by WHO (1 999) 
mainly considered etiological basis in classify ing diabetes. 
According to present classification diabetes are mainly four types whieh are shown in 
table I . 
Table 1: Etiological Classification of Diabetes Mellitus (WHO, 1999) 
A. Type I (beta- cell destruction, usually leading to absolute insulin defi ciency) 
• Type I A- Autoimmune mediated type 
• Type I B- Non- immune mediated idiopathic type 
B. Type 2 (may range from predominantly insulin resistance with relati ve insulin 
defi ciency to a predominantly secretary defect with or without insulin 
resistance). 
C. Other specific types 
D. Gestational diabetes 
Type 1 Diabetes Mellitus (TlDM) 
T I DM is characterized by abrupt onset, mainly occurs before the age of 20 years (i .e. in 
childhood or ado lescence), but may be di agnosed at any age, usually to patients who are 
lean. It contributes to about 10% of the diabetics' worldwide (ADA 1997). The incidence 
of T I DM has been found to be lowest in Asia (0.1 per 1000,000 in China) and highest in 
Scandinavia (35 .5 per 1000,000 in Finland). The underl ying pathophysiologic defect in 
T I DM is main ly thought to be resulting from selective B cell s. These pati ents usually 
have very low level of endogenous insulin and need insulin supplementation for survival. 
Type IA DM: T IDM are fo und to be associated with number of islet specific 
autoantibodies. These include insulin autoantibody (IAA), Islet cell antibody (ICA), 
glutamic acid decarboxylase (OAD65) antibody and anti tyrosine phosphatases (Anti-
IA, ) anti body. One or more of these autoantibodies are found to be present in 85-90% of 
ind ividuals whcn tasting hyperglycemia is initiall y detected. It also has strong HLA 
associations, Witll linkage to the DQA and DQB genes (Donner el aI. , 2000), and it is 
influenced by ti,e DRB genes. These HLA-DRiDQ alleles can be e ither predi sposing or 
protecti ve. 
Type I B OM : Some of these pati ents have permanent insul inopenia and are pro ne to 
ketoacidosis, but have no ev idence of association of autoimmunity in its pathogenesis. 
Although only a minority of pati ents (usually obese teen) with T I DM fa ll s into thi s 
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category, o f which are mostl y Afri can and As ian 111 ancestry (McLarty el aI. , 1990; 
Tanaka el aI. , 2000). 
Type 2 Diabetes Mellitus 
T2DM is characterized by impairment In insulin secretion and res istance to insulin 
action/or both. It is the most common form of di abetes and one of the most frequent 
metabo lic di sorders world wide that contributes to more than 95% of all diabetics in most 
populations. 
In Ameri can Indians and South Pac ific Islanders, T2DM is the onl y form of the di sorder. 
Overall prevalence of diabetes varies between 15-20%. The highest prevalence ofT2DM 
(50%) was fou nd among Pima Indians (49.4% in male and 51.1 % in female) in USA and 
Nauru (4 1 %; male 40.0% and female 42%) and a very low (0-1.4%; male 0% and female 
1.4%) was observed among the Mapuches population in Chile and the prevalence was 
almost nil in rural and peri -rural populati on o f Papua New Guinea (WHO 1994). In the 
non- Euripides population the preva lence has been shown to vary fro m < I % in rural 
Bantu of Tanzania and Mainland China to 40-50% in Pima Indians (USA) and Nauru 
(King and Rewers, 1993). Age-standardi zed prevalence of T2DM among native Asians 
and non-Indian Asians demonstrated an increased trend from rural to urban and 
markedly increased trend among the migrants to the west and affluent countries. A 
similar trend also has been observed among native and migrant Pacific Is land 
populations (Coughlan el 01., 1997). In multiethnic US society the prevalence of diabetes 
has shown to vary among different ethnic groups; 5% in the Caucasian origin, 10% in 
Afri can-Americans, 16% in Cuban origin and 26% in Puerto Ricans (Harris 199 1; Flegal 
el aI. , 199 1). Studies invo lving rural and suburban population in Bangladesh revealed the 
prevalence ofT2D to be 4.3% and 4.1 % respecti vely (Sayeed el aI. , 1997 and 2003). 
Pathological basis of Diabetes Mellitus 
Environmental fac tors are found to play strong role in geneticall y susceptible cases in the 
pathogenesis of di abetes in both type 1 and type 2 variety. 
Environlllental factors 
A number of environmental factors implicated in the pathogenesis of type I and type 2 
varieties, which include age, di et, and viral infec tion and stress (Knip and Akerblom 
1999; Dahlqu ist 1998). 
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Age: Glucose to lerance has been shown to decrease with age (Shimokata et al., 1991). 
However, whether the deterioration is caused by increased chronological age or 
secondary age related factors, such as decreased physical activity, is still to be clearly 
understood. 
Virus: Coxsackie VIrLIS B (CVB), rubella, cytomegalovirus (CMV) and Epstein-Barr 
viruses (EPV) are the most important viruses that have been implicated in the 
pathogenesis of diabetes. Infections through these viruses are known to have systemic 
effects on the pancreas. Coxsackie B4 virus is strongly associated with the development 
of T I OM in humans and shares sequence similarity with the islet GAD65 (Horwitz et 
ai, 1998). About 12-20% patients with congenital rubella syndrome (CRS) develop 
TIDM within 5-20 years of age. CMV and EPV have also been associated with newly 
diagnosed TI OM (Hassan, 2006). 
Diet: Diets with high-fat, low-carbohydrate impair the action of insulin on endogenous 
glucose production, glucose oxidation, and probably lipolysis but it does not clearly 
affect the action of insulin on total glucose disposal and tend to enhance the action of 
insulin on non-oxidative glucose disposal (Bisschop ei ai., 200 I). Intakes of excessive 
amounts of saturated fats have lead to obesity in individuals, who were found to be more 
susceptible to develop insulin resistance (Lovejoy et ai, 200 I) . 
Obesity: The major environmental risk factor for T2DM is obesity and a sedentary 
lifestyle (Bleich et aI., 2007). Thus, the tremendous increase in the rates of T2DM in 
recent years has been attributed, primarily, to the dramatic rise in obesity worldwide 
(Zimmet et ai, 200 I) . It has been estimated that approximately 80% of all new T2DM 
cases are due to obesity (Lean, 2000). This is true for adults and chi ldren. In the Pima 
Indians, 85% of the T2DM chi ldren were either overweight or obese (Fagot-Campana et 
ai, 2000). Although excess weight and obesity (BMI>25 kg/m2) account for 64% cases 
of diabetes in men and 74% in women, many cases of diabetes occur in lean subjects 
(Chan el aI. , 1994; Colditz el al., 1995). 
Sex: Some studies had showed a higker age-adjusted prevalence in women (Eriksson et. 
al., 1993), where as some investigators demonstrated male preponderance (Lintott et aI., 
1992). Variation in T2DM prevalence between men and women also has been shown to 
vary in different age group in the same community. 
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Stress: Stress has long been suspected as having important effects on the development of 
diabetes. Slawson et al ( 1963) showed that 80% of a group of 25 adult diabetes patients 
gave a hi story of antecedent stress mainly in terms of losses, 1-48 months prior to the 
onset of diabetes. These were mostly patient of depression. Metabolic stress may develop 
due to disproportionate amount of free radical productions in diabetes by glucose 
autox idation, polyol pathway and non-enzymatic glycation of proteins. In a study, 
ox idative stress pathway markers 111 the diabetic patients, type I and type 2, was 
compared to normoglycemic subjects. The increased level of glycosy lated hemoglobin 
was observed in the diabetic patients and thi s increase is directly proportional to the 
blood glucose level (Strain el al. 1991). This suggests the increase in oxidative stress due 
to hyperglycemia. 
Hypoinsulinaemia in diabetes increases the activity of the enzyme fatty acyl coenzyme A 
ox idase, which intiates p-oxidation of fatty acids, resulting in lipid peroxidation, which 
impairs membrane function changing the activity of membrane-bound enzymes and 
receptors (Halliwell el al., 1997). 
Genctic factor's 
Genetic susceptibility has been implicated in the pathogenesis of both Type I and Type 2 
diabetes. TIOM accounts for approximately 5- 10% of all cases of diabetes with the 
major susceptibility gene mapping to the HLA region of chromosome 6 (Herr el aI., 
2000). It has been estimated that HLA provides up to 40-50% of familial clustering in 
TIDM (Noble el al., 1996). The HLA region is a cluster of genes located with major 
hi stocompatibi lity complex (MHC) on chromosome 6p21. The HLA complex is 
classically divided into four regions, known as class I, class II , class III and class IV 
(Gruen and Weissman, 1997). The class II MHC region encodes the class II HLA 
molecules which are involved in immune process and turn out to be important candidate 
in the pathogenesis of TI OM. Among other gene locus found to be implicated with 
TIOM are in chromosome 4pl5 (Sawicki et al. , 1997; Hayes et ai., 1998), chromosome 
2q 13 , chromosome 2q3-2q34 (Morahan el al., 1996; Larsen el ai., 1999) and 
chromosome 6q21 (Temple el ai., 2000). 
Family aggregation of the di sease showed higher prevalence for T20M. In TI OM cases 
more than 80% of the newly diagnosed individuals had no familial diabetic history 
(WHO 1999). However, the children of TlDM mothers showed lower risk to diabetes 
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compared to T IDM fathers ( !.7±0.6% vs 4.1±0.9%) (Tilli and Koberling, 1987). In a 
study, siblings where showed to have 10.4% prevalence to T2DM, but if one or both 
parents were affected the prevalence was 17.8% and 25.2% respectively (Klein et al., 
1996). In another study, life-time risk of developing T2DM in offsprings was 40% with 
Olle diabetic pa rent and 70% with both parents have the disease (Groop el al., 1996). The 
CODIA13 Study in France showed that 66% T2DM patients had atl east one relative with 
diabetes. Diabetes was found to be 4-fold increased risk for T2DM in siblings of a 
diabetic proband compared with the general population (AS of 3.5 to 4) , the odds ratio 
(OR) of 3.4- 3.5 with only a single affected parent, and the increase in the OR to 6.1 if 
both parents are affected (Meigs and Cupples 2000). 
Multiple studies of twin concordance raies have been undertaken in understanding of the 
genetic basis of diabetes. The concordance rate for T IDM among monozygotic twins 
was reported between 2 1 % to 70% (Barnett el . al., 198 1) and 13% in dizygotic twins 
(Kumar el . aI., 1997). In the same study by Barnett et. a!. , ( 198 1) showed concordance 
rate for T2DM in monozygotic twins to be 9 1 %. Estimates for concordance rates have 
ranged from 0.29 to 1.00 in monozygotic (MZ) twins, while in di zygoti c (DZ) twins the 
range was 0. 10-0.43 (Barnett et al., 198 1; Newman et al ., 1987; Poulsen el al. , 1999). 
Concordance among both MZ and DZ twins increases with the duration of follow up 
period (Medici e l al., 1999). In spite of several caveats in twin studies, the high 
cQncordance in MZ twins and the 50% fall in DZ twins providc compelling evidence for 
a genetic component ofT2DM. 
Monogenic form accounts for approximately 10% of all cases of the condition constitute 
a field where substantial progress has been made in the dissection of the molecular 
background of T2DM. Monogenic form of T2DM with profound defect in insulin 
secretion include subtypes of maturity onset diabetes of the young (MODY), maternally 
inherited diabetes with deafness (M IDD) caused by mitochondrial mutations, and rare 
eases resu lt ing fro m insulin gene mutations. The majority of proteins associated with 
MODY are transcription factors, such as hepatocyte nuclear factor 4u (HNF-4u), HNF-
la, insulin promoter factor-I (lPF-I), HNF-I~, and NEUROD!. They influence 
express ion of the other genes tlu'ough regulation of mRNA synthesis. Only MODY2 
form is associated with glucokinase, a key regulatory enzyme of the B cell. There are 
striking differences in the clinical picture of MODY associated with glucokinase and 
MODY associated with transcription factors. Three monogenic forms of T2DM 
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characterized by severe insulin resistance are the consequence of mutations in the 
PPARy, ATK2, and insulin receptor genes, These forms ofT2DM have a middle/ late age 
or onset and occur with both impaired insulin secretion and insulin resistance, Their 
clinical picture is created by the interaction of environmental and genetic factors, such as 
frequent polymorphisms of many genes, not just of one, These polymorphisms may be 
localized in the coding or regulatory parts of the gencs and are present, although with 
different frequencies, in T2DM patients as well as in healthy populations. Sequence 
differences in a few genes have been associated, so far, with complex, polygenic forms 
of T2DM, for example, calpain 10, PPARy, KCJN II, and insulin. In addition, some 
evidence exists that genes, such as adiponectin, IRS-I, and some others may also 
innucncc the susceptibility to '1'2DM (Malecki, 2005). 
No T2DM gene susceptibility has been identified as that of the magnitude of HLA in 
'1'1 DM. However, several chromosomal regions have been found in strong linkage with 
T2DM. Some of the loci have shown linkage in more than one population. Important 
hotspots for '1'2DM have been identified on chromosome 2q37 (Hanis el al., 1996), 
chromosome 12q24 (Mahtani el al. 1996), chromosome 20q 12-q 13 (Bowden el al ., 
1997), chromosome I q21-q23 , chromosome 3q27 (Vionnet el al., 2000) and 
chromosome 8q21.3-22 (Wiltshire el al., 200 I). These factors have been primarily 
sought using the candidate gene approach and the genome-wide scan approach. 
To date, more than 50 candidate genes for T2DM have been studied in vanous 
populations worldwide. However, results for essentially all candidate genes have been 
connicting. Use of this approach has identified a number of candidate T2DM 
susceptibility genes such as PPARG, KCJN II , ABCC8 and CAPN 10 (Barroso, 2005). 
Positional cloning of genes have identified CAPN to as the only candidate till date, in the 
T I DM region of chromosome 2 to be associated with T2DM (Horikawa el aI. , 2000). 
The first such study conducted a genome wide scan on 170 Mexican-American fami lies 
and found linkage near the terminus of chromosome 2q37 (lod = 3.2, P < 10-4). This 
susceptibility locus, NIDDM I, originally encompassed 10- 20 cM, but the target region 
was subsequently narrowed to 7cM. A genomic contig was constructed encompassing 
1110st of the 7 cM NIDDM 1 interval that is li kely to include a predisposing gene for 
T2DM (Horikawa el al., 2000), The authors identified a total of 214 polymorphic sites 
across thi s region and tested fo r association with T2DM and for evidence of linkage. At 
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NIDDM 1, live sing1enucleotide polymorphisms (SNPs) showed a difference for allelic 
frequencies between patients and controls, so Horikawa et al (2000) sequenced 
approximately 60 kb in this region, revealing two genes and one expressed sequence tag. 
One gene, designated cal pain 10 (CAPN 1 0), encodes a new member of the cysteine 
protease family , and the other encodes G protein- coupled receptor 35 (GPR35). Both of 
these genes were shown to be ubiquitously expressed in ti ssues, including pancreatic 
islets and skeletal muscle. None of the coding region SNPs in CAPN 1 0 or in GPR35 was 
associated with the di sease or with the evidence for linkage. However, one SNP 
(UCSNP-43) in intron 3 ofCAPN10 showed an increase in the frequency of the common 
CALPAIN 10 
Cal pains are a family of calcium-activated, neutral , nonlysosomal proteases. They have 
been proposed to be implicated in the regulation of a variety of cellular functions and 
may be responsible for adipocyte differentiation (Patel and Lane, 1999) as well as 
insul in-induced down-regulation of insulin rcceptor substrate-I , a key mediator of insulin 
acti on (Smith ef aI., 1996). 
CAPN lOis a member of the calpain superfamily (Guroff, 1964; Dayton ef al., 1976). 
Calpains are often subdivided into three separate classes, the typical calpains (calpain 1, 
2,3, 8a, 9,11,12 and 13), the calpain small subunits (caJpain 4 and 14) and the atypical 
calpains (calpain 5, 6, 7, 8b, 10 and 15). This classitication is based upon domain 
structure (Figure 1). The large subunit contains domains (D) I, 11, III and IV. Domain 11 
comprises the active proteolytic domain , domain 111 contains the C2-like region, and 
domain IV contains multiple Ca2+/calmodulin-like (CaM) EF hands. The smaller subunit 
consists of domains V and VI , the latter al so containing multiple Ca2+/calmodulin-like 
EF hands. Domain structure resembles that of the large subunit of typical cal pain, with 
the notable exception of the presence of a T-domain of an unknown function in place of 
domain IV. Atypical calpains are monomeric, and hence have no small subunit. Domains 
which contain Ca2+-binding sites are present in both typical and atypical cal pains. 
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Figure 1. Calpain protein domain structure and function (Turner el al., 2005). 
Ma et al (2000) first cloned calpain 10 in 2001 and p'roposed that this calpain isoform 
was locali zed to the cytosol and translocated to the nucleus after increases in cellular 
ci+. Arrington et al (2006) revealed cal pain 10 to be present in the cytosol and 
mitochondria, while significant nuclear staining is absent under nonstimulated 
condi tions. 
Cal pa in 10 levels in ti ssues vary; are highest in the heart, fo llowed by the brain, liver, 
ki dney, and pancreas in humans. At least eight spli ce vari ants of cal pain 10 (calpains l Oa 
th rough 1 Oh) have been identi fied, including three variants that lack intact domain II and 
thus have no protease acti vity (Horikawa el aI., 2000). Some cal pain lOis detectable in 
the soluble fraction by Western blotting using an antibody raised against a synthetic 
peptide, but it is preferentiall y found in the water-i nsoluble fraction in rat ti ssues (Ma el 
al. 2000) . 
Short-term exposure of mouse pancreati c i, IeLs to ca l pain inhibitors cnhanced glucose-
induced insulin secretion but reduced insulin-stimulated glucose uptake into adipocytes 
and skeleta l muscle, and reduced glycogen synthesis rates in muscle. This partly supports 
the above consideration, but the exact site of calpain action in the insulin-signaling 
pathway is not clear. But as cal pain inhibition showed similar reduced effects on a 
hypox ia-associated increase in glucose uptake, which is not mediated by the insulin 
receptor system, the cal pain regulated step might not be directly invo lved in this pathway 
(ltani el ai, 2000). The protease acti vity of ca lpain 10 has not yet been analyzed. Its 
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calcium sensitivity appears to be signi ticantl y different from typical cal pains on the basis 
of the structure. 
CA PN I 0 polymorphism has been associated with T20M as we ll as insulin acti on, 
insulin secretion, aspects ofadipocyte biology and microvascular function. However, this 
has not always been with the same single nucleotide. polymorphism (SNP) or haplotype 
or the same phenotype, suggesting that t11ere might be more than one di sease-associated 
CAPN I 0 variant and that these might vary between ethnic groups and the phenotype 
under study. Cal pain-I 0 is also an important molecule in the beta-cel l. It is likely to be a 
determinant of fuel sensing and insulin exocytosis, with actions at the mitochondria and 
plasma membrane respecti vely. The multiple actions of calpain-IO may relate to its 
diffe rent protein isoforms. 
Cal pain plays roles in membrane fusion (Barnoy el aI. , 1999) and hydrolyzes various 
proteins that participate in cell ular signaling, such as kinases, receptors, and transcription 
lilctors. Further, ca lpa in is also important for di fferenti ati on of preadipocytes into 
adipocytes. These facts raise the possibility that cal pain modulates both insulin secretion 
and action. In skeletal muscle, liver, and pancreas, several calpain species are expressed, 
including typical and atyp ical cal pains. Studies on the action of cal pain using calpain 
inhibi tors suggest that ca l pain species other than calpain 10 also participate in insulin 
secretion and action and susceptibi lity to T20M. Because many steps could be 
modulated by ca lpa in , further precise experiments are essential to clarify the molecular 
and physio logica l mcchanism cxplaining the assoc iation of cal pain with type 2 diabetes . 
CALPAIN 10 (CAI'N 10) GENE 
The human CAPN 10 located on chromosome on chromosome 2q37.3 compnses 15 
cxons and spans 31 Kb of genomic sequence. This sequence encodes the 672 amino acids 
of the full-length calci um-dependent cysteine proteases, participating in hydrolys is of 
specific substrates important in calcium-regulating signali ng pathways. A genetic variant 
of CAPN I 0 may alter insuli n secreti on, insulin action, and the producti on of glucose by 
the liver (I-Iorikawa el aI., 2002). 
Genetic variants in the CAPN 10 fo und to be associated with elevated free fatly acids 
and insulin resistance (Ortho-Malender, 2002). In vitro studies have shown that free fatty 
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acids activate protein kinase C, which results in hyperphosphorylation of insulin 
receptors, leadi ng to reduction in the kinase activity of insulin receptors and thus 
cnhancing insulin resi stance (Griffin el ai., 1999). Therefore, downregulation of protein 
kinase C activity appears to be an important factor to maintain proper phosphorylation 
levels of insulin receptors Otani el 01., 2000). 
Polymorphism within intron 3 of CAPN 10 (SNP-44) has been suggested to be located as 
an enhancer element and might regulate CAPN 10 expression. A meta-analysis showed 
that the SNP-44 allele 2 was associated with the increased ri sk of T2DM (Song el ai., 
2007). 
SNP-44 results by a T504A substitution in domain III (domain T) of calpain 10 amino 
acid sequence, suggest ing that the synthesis of a mutant protein and/or altered 
transcriptional regulation could contribute to diabetes risk. A combination study 
comparing SNP-44 with SNP-19, -43, -63, showed greater transmission of diabetes. A 
sign ificant increase (P=0.033) was observed in transmission of C allele at SNP-44, to 
affected offspring in parents-offspring trios (odds ratio 1.6). [t revealed a significant over 
difference of an excess of allele 2 of SNP-44 in the trios probands, compared with that in 
the population controls (0.23 vs. 0.16; 1'=0.005) (Evans el 01. , 200 1). 
A stud y showed that the 11121122 1 diplotype defined by SNP-44/431l9/63 in CAPN 10 
gene was associated with the reduced risk of diabetes and hypertension in this studied 
population. Since the allele 2 of SNP-44 almost wholly occurred on the common 
haplotype 21 11, with frequencies of the 2112, 2[21 and 2221 haplotypes less than 0.5% 
in thi s population, the 111211 221 diplotype in the present study is equivalent to the 
11 2/22 1 diplotype in Mexican-American of Horikawa's study. This finding was 
consistcnt with the result of a small-size sample study in southern Chinese and the first 
examined group of Mexican-American . However, the study in South Indians suggested 
that thi s diplotype appeared to increase risk for impaired fasting glucoselimpaired 
glucose tolerance and T2DM (Chan el 01. , 2007). 
Other meta-analyses suggested that increased risk ofT2DM is associated with both SNP-
43 and SNP-44 and that these polymorphisms may form the basis of an approach to 
predict the condition. Studies on nondiabetic British subjects with high ri sk haplotype 
( 11 2/ 12 1) had increased plasma glucose levels both at fasting and after a 2-h oral glucose 
tolerance test concomitant with a decrease in the insulin secretory response. Consistent 
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with thesc data, polymorphism at SNP44 was found to modify the plasma glucose curve 
obtained from an oral glucose tolerance test in a manner that was indicative of T2DM 
assoc iation (Harris el aI., 2006). 
DIABETES IN BANGLADESH 
Diabetes in Bangladesh follows a similar pattern that to worldwide. Overall prevalence 
of diabetes in Bangladesh was found to be 7% (Sayeed el ai., 2007). However in their 
previous report it was about 6.6% (Sayeed el aI., 2004). The group reported higher 
prevalence of diabetes mellitus among the tribal population compared to the mainstream 
Bangladesh. As expected prevalence of diabetes found to be much higher in the Urban 
community (II %) compared to the rural counterpart (4%). However, surprisingly much 
higher impaired glucose tolerance was observed among the rural dwellers. 
Another study based on rural community revealed higher prevalence in men compared to 
women (9.4% vs 8.0% respectively) (Ralunan el ai., 2007). About 7% of all diabetics 
registered at BIRDEM are reported to be of young onset type (below 30 years of age). 
Th<:y do not fit either to type I or type 2 diabetes mellitus. About 13% of these young 
onset diabetic patients have features of pancreatitis which are termed as fibrocalculus 
pancreatic diabetes (FCPD) (Azad and Ali, 1997). 
Studies were undertaken to understand the pathophysiology of T2DM in Bangladeshi 
population. Newly diagnosed, both normal weight and overweight patients were reported 
to have both insulin secretory dysfunction and insulin resistance with form being 
predominant in pathophysiology T2DM (AI-Mahmood, 2000). The extent of insulin 
secretory dysfunction was higher compared to loss of insulin sensitivity in obese type 2 
subjects (Junaid, 2000). 
Both insulin secretory defect and insulin resistance are predominantly present in the 
pathogenesis of these T2DM. However the basis of the pathogenesis of the T2DM is to 
be clearly understood. As a part of series of experiments to elucidate pathological basis 
of T2DM in Bangladeshi population, the present study was undertaken to investigate 
CAPN I 0 gene common polymorphism in the Bangladeshi T2DM patients. It is of 
importance to determine novel genetic variants in the .Bangladeshi diabetic subjects to 
understand its etiopathogenesis. 
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Chapter 2 
REVIEW OF LITERATURE 
Review of Liter'ature 
Calpuin is a cytoplasmic cysteine protease requiring calcium ions for its acti vity. 
Although its physiological function is still not fully understood, it is implicated 111 a 
vari ety of calcium-regulated cellular processes such as signal transduction, cell 
pro liferation, cell cycle progression, di fferentiation, apoptosis, membrane fusion, and 
platelet acti vation (Sorimachi el aI. , 1997; Huang el aI. , 200 I ). Deregulation of its 
acti vity has becn implicated in vari ous pathological conditions such as neuronal 
degeneration, Alzheimer' s di sease, metastasis, and cataract. 
Cal pain has attracted much attention because of the recent d iscovery of correlations 
between ca l pain gene mutations and human diseases, together with e lucidation of its 
three-dimensional structure and calcium-induced activation mechanisms (Hosfield el a/., 
1999; Strob l el aI. , 2000). Positional cloning of genes responsible for diseases has 
revealed association of the calpain 10 gene (CA PNI O) with type 2 diabetes, but 
information on molecular and physiological mechanisms ex plaining the association of 
th~ calpain 10 gene with type 2 di abetes remains unclear and limited (Hirokawa el a/. , 
2000). 
Propcrtics and structure of Calpain 
Cal pain is not specific for certain amino acid residues or sequences but recognizes bonds 
between domains. As a consequence, calpain hydrolyzes substrate proteins in a limited 
manner, and large fragments retaining intact domains are produced by hydrolysis. 
Calpain is regarded as a bio-modulator, because properties of the substrate proteins are 
o ften modulated upon hydro lys is by calpain (Sorimachi el al., 1997; Huang el al., 2001). 
Two cal pain (Il-ca lpain and m-ca lpain) activities are detected when tissue extracts are 
separated by Diethylaminoethyl co lwnn chromatography. These correspond to two 
convent ional calpain species in mammals: Il-calpain and m-calpain. They are 
heterod imers composed of a large 80-kDa catalytic subunit and a common 30-kDa 
r~ gu latory subunit. These contain fO llr (I- IV) and two (V and V I) domains, respecti vely. 
The protease domain II , like other cysteine proteases such as cathepsins B and L, is 
composed of two subdomains (I1a and lib) with its substrate binding cleft in-between. 
The active site Cys-l05 on lIa is 10 angstrom apart from other catalytic triad residues 
(His-262 and Asn-286) on lib, indicating that lIa and lib are slightly too separated and 
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open to constitute a functional catalytic triad (Hosfield el ai. , 1999; Strobl el ai., 2000). 
Thi s inactive conformation of domain II is stabilized by interaction of domain I with 
domain VI on one side and interaction of Ilb with domain Ill, especially an acidic loop, 
on the other side (Strobl el ai., 2000). Domain III has no apparent sequence homology to 
other proteins, but its higher order structure resembles C2 domains found in 
phospholipase C, protein kinase C, synaptotagmin, etc., and it binds Ca2+ and 
phospholipids (Hosfield el aI. , 1999). Both domains IV and VI contain five sets of EF-
hand Ca2+-binding motifs similar to those found in calmodulin. The extreme COOH-
terminal fifth EF-hand motif in IV and VI cannot bind Ca2+ but interacts with each other 
to form a heterodimer comprising SOK and 30K. The NH2-terminal domain V of 30K is 
rich in glycine and cannot be seen in the crystal structure because of its mobile 
confo rmation. 
This dissociation theory of cal pain, although a full consensu~ has not yet been reached, is 
apparently consistent with the existence of various 80K homologues that appear to 
function without 30K. Dissociated 30K might have a function different from proteolysis 
after forming a homodimer (Pal and Elee, 2001). Both fl- and m-calpains and 80K 
homologues are inhibited by reagents that react with the active site cysteine residues, 
such as E64, leupeptin, and N-Ac-Leu-Leunorleucinal (Sorimachi el aI. , 1997). These 
inhibitors also react with other cysteine proteases and are not spec ific for cal pain. The 
nonpeptidic inhibitor PD 150606 inhibits cal pain by interacting with the calmodulin 
domain. This inhibitor is relatively specific for cal pain , and the inhibition mechanism is 
different from other inhibitors (Wang el ai., 1996). 
An endogenous cal pain inhibitor, calpastatin, exists m the cytosol. It contains four 
equivalent inhibitory domains of 140 residues, having three conserved regions (A, B, and 
C) that are important for inhibition. A and C interact with IV and VI, respectively, in a 
C}+-dcpcndcnt manner. and B shows inhibitory activity by itself, probably by binding at 
or near the active site (Tompa el al., 2002). Presence of the two calmodulin-like domains 
IV and VI are necessary for effective inhibition by calpastatin. Thus, calpastatin inhibits 
only dimeric calpain (namely fl-calpain , m-calpain, and calpain 9) with 30K. Calpain 
SOK homologues including cal pains I and 2 are not inhibited and thus escape from the 
regulatory actions of calpastatin. 
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All members of ca lpain family abundant in human cells are now known, many of which 
nre associated wi th human disease (I-luang el ai., 200 I). Cal pains 1 and 2 are implicated 
in causing injury to the brain after a stroke and also have been linked to the pathology 
seen in Alzheimer's di sease. Cal pain 3 is mainly found in the muscle, and mutations 
cause limb-girdle muscular dystrophy. Mutations of calpains in the worm Caenorhabdi/is 
elegans affect sexual development (Barnes el 01. , 1996), and mutations of a calpain-like 
gene in the fl y cause a degeneration of parts of the nervous system (Delaney el 01. , 199 1). 
Activation m echanism of C alpain 
Cal pain exists in the cytosol as an inactive enzyme and trans locates to membranes in 
response to increases in the cell ular Ca2+ level. 
At the membrane, cal pain is acti vated in the presence of Ca2+ and phospholipids. 
Autocatalytic hydrolysis of domain I take place during acti vation, and di ssociation of 
30K li'om 80K occurs as a result. Acti vated ca l pain or 80K hydro lyzes substrate proteins 
at mcmbranes or in cytosol after release from membranes (Suzuki el 01., 1995) . 
In the absencc of Ca2+, two protease subdomains lIa and lib are separated by structural 
constraints imposed by domain interaction. Ca2+ -induced structural changes that release 
the constraints are prerequisite fo r activation to form a functional catalytic site. Recent 
X-ray structural analyses have revealed a Ca2+ -induced activation mechanism at the 
molecular level. There are at least three di fferent Ca2+-binding sites in m-calpain, two 
ca lmodulin-li ke domains IV and VI , an acidic loop region in C2-like domain III , and a 
protcase domain II. A proposed mechanism for acti vity regulation of m-calpain by Ca2+ 
compriscs two stages (F ig. 2). The first stage is the release of constraints imposed by 
domain interactions. Binding or Ca2+ to domains IV, VI, and III releases domain I from 
V I and domain II fro m III and leads to dissociation of 30K from 80K. The second stage 
is the rearrangement of the active site cleft caused by bindi ng of two Ca2+ atoms to the 
protease domain (one each to the lIa and lib subdomains) . Activation by the second stage 
occurs only after release of the constraints freed by the first stage (Moldveanu, 2002). 
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Figure. 2. Activati on mechanism of calpain by Ca>+' Binding of Ca' + and phospholipids (PL) 
to m-ca lpain induces conformational changes, which brings Jla and JIb closer together to form 
a functi onal catalytic site and causes dissoc iation of 30K from SOK, resulting in 30K 
homodimer formation. There are at least three different calcium-binding sites in m-calpai n, 
two calmod ulin like EF-hand structures in domains IV and VI , an acidic loop in domain III, 
and two non- EF hand calc ium-binding sites in Jla and JIb. C I 05 and H262 are catalytic 
residues. K 7 and D I 54 form a salt bridge in the absence of calcium ions. Cal +, ca lcium atom 
bound to ca lpa in ; Nt, NH2-terminal res idue; + and -, basic and ac idic amino acid residues 
imporlant tcr binding of calcium ions. (Suzuki e/ al., 2004) 
The two-stage activation mechani sm is a general mechani sm applicable to calpains 
without 30K or atypical calpains, because the protease domains are always composed of 
lIa and lib, and the calcium-coordination residues for the two Ca2+-binding sites in I1a 
and lib are conserved among cal pains (Sorimachi e/ aI. , 200 I , Moldveanu, 2002). In the 
cases of ca l pains without 30K or without domain III or IV, the first stage of activation 
might be bypassed and they are activated directly by the second stage. Autolysis of 
domain I facilitates di ssoc iation of 30K from 80K (Nakagawa el aI., 2001), and binding 
of Ca2+ at domain 1lI is responsible for translocation of calpain to membranes, as 
observed with protein kinase C and phospholipase C (Tompa el aI., 2001). 
Acti vity of ealpain is tightl y regulated both temporally and spatially mainly by Ca2+, 
because deregulation of calpain activity causes excessive degradation or accumulation of 
coc~ i sting cellular proteins resulting in serious cellular damage and pathological 
conditions. Phosphorylation o f calpain might be another important mechani sm for 
acti vity regulation. Phosphorylation of cal pain at Ser-369 in domain III by protein kinase 
A restricts domain movement and freezes m-calpain in an inactive state (Shiraha el aI., 
2002). 
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Function of Calpains 
Cal pains arc cytoso lic enzymes implicated in numerous cellular functions and 
pathologies. Arrington et al (2006) identitied a mitochondrial Ca2+-inducible protease 
that hydrol yzed a calpain substrate (SLL VY -AMC) and was inhibited by active site-
directed cal pain inhibitors as calpain 10. Immunoblot analysis and activity assays 
revealed cal pain lO in the mitochondrial outer membrane, intermembrane space, ilmer 
membrane, and matrix fractions. 
Mitochondrial sta ining was observed when COOH-terminal green fluorescent protein-
tagged ca l pain 10 was overexpressed in NIH-3T3 cells and the mitochondrial targeting 
sequence was locali zed to the N H2-terminal 15 amino acids. Overexpression of 
mitochondrial cal pain 10 resulted in mitochondrial swelling and autophagy that was 
blocked by the mitochondrial permeability transition (MPT) inhibitor cyclospori ne A. 
With the use of isolated mitochondria, Ca2+-induced MPT was partially decreased by 
cal pain inhibitors . Ca2+-induced inhibition of Complex I of the electron transport chain 
was blocked by cal pain inh ibitors and two Complex I proteins were identified as targets 
of mitochondria l cal pain 10, NDUFV2, and ND6. Calpain 10 was the first to be reported 
mitochondrially targeted calpa in and a mediator of mitochondrial dysfunction through 
the cleavage of Complex I subunits and activation of MPT (Arrington el 01., 2006). Their 
proposed model is shown in ti gure below: 
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Figure. 3. Proposed mechan ism of action for calpain 10-medi ated ETC dys function. Depicted 
above is a schematic diagram of the proposed mechanism of ca lpa in 10 action after Ca" -
in duced mitochondri al dysfuncti on. After inj ury, increases in cytoso lic Ca" are translated to 
the mitochondria via the ruthenium red-sensitive calcium channel uni porter. Increases in 
matri x Ca" acti vate mitochondri al calpain 10, inducing cleavage of two critical subunits of 
Complex I, ND6 (*) and NDUFV2 (#), lead ing to subsequent respiratory defi cits. Increases in 
mitochondrial ca lcium also contribute to the induction of MPT, poss ibly through proteolys is 
of membrane pore proteins. (Arrington el al., 2006) 
In anot her study, (Paul el 01.. 2003) inhibition of ca lpain acti vity has been shown to 
red uce insulin stimulated glucose uptake in iso lated rat-muscle strips and adipocytes. 
They exami ned the mechani sm by which cal pain affects insulin-stimulated glucose 
uptake in 3T3 -L I adi pocytes. Inhibition of cal pain activity resulted in approx. a 
60%decrease in insulin-stimulated glucose uptake. Furthermore, inhibition of cal pain 
acti vity prevented the translocation of insulin-responsive glucose transporter 4 (GLUT4) 
vesicles to the plasma membrane, as demonstrated by fluorescent microscopy of whole 
cc ll s and isolated plasma membranes; it did not, however, alter the total GLUT4 protein 
content. Whi le inhibition o f calpain did not affect the insulin-mediated prox imal steps o f 
the phosphoi nosi ti de 3-ki nase pathway, it did prevent the insulinstimulated corti cal actin 
reo rgani zation req ui red fo r GLUT4 trans location. Specific inhibition of calpain 10 by 
antisense expression reduced insulin-stimulated GLUT4 translocation and actin 
reorganization. Based on these findings, a role was proposed for calpain in the actin 
reorgani zation required fo r insul in stimulated GLUT4 translocation to the plasma 
membrane in 3T3 -L1 adi pocytes. These studies identify cal pain as a novel factor 
invo lved in GLUT4 vesicle trafficking and suggest a 'Ii nk between calpain acti vity and 
the development of type 2 diabetes. The overall summary is briefl y described below: 
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(I) Glucose enters B cells through GLUT2 transporters. The ensuing result is glycolysis 
and an elevated A TP: ADP ratio generated by mitochondria. The ability of mitochondria 
to perform thi s function has been shown to be severely diminished by calpain inhibition, 
and calpain-IO is thus hypothesized to function as a regulator of mitochondrial fuel 
sensing (Zhou el ai., 2003). 
(2) With the exception of pre-docked granules primed [or I st phase secretion, secretory 
granules are fo r the most part found at sites distal to the plasma membrane. Following 
the initial burst of secretion from pre-docked granules, subsequent exocytotic granule 
fusion requires the recruitment of granules from deep within the cell. This is a process 
that requires cytoskeletal rearrangement and the concomitant transport along 
microtubules of secretory granules (Burgoyne and Morgan, 2003; Goldstein and Yang, 
2000; Tang, 200 I), or in the case of skeletal muscle and adipocytes GLUT4-containing 
vesicles (Kanzaki and Pessin, 2003; Watson el ai., 2004), to active si tes of exocytosis at 
the plasma membrane. The process of actin cytoskeletal rearrangement is sensitive to 
cal pain inhibition, both phannacologically or through use of specific CAPN I 0 antisense 
oligonucleotides (Paul el ai. , 2003) and the actin cytoskeleton is a common target for 
cal pain-mediated proteolysis in numerous cell types. 
Brown et al (2007) have shown that targeted suppression of calpain-I 0 expression III 
cultured human skeletal muscle cells impaired insulin-stimulated glucose uptake. The 
degrec of suppression of CAPN I 0 gene expression was in line with that observed in 
insulin resistant subjects at increased risk of T2DM. This suggests that the observed 
degree of suppression in these subjects may contribute directly to the skeletal muscle 
insulin resistance. 
(3) The final step in the secretory pathway is the actual exocytotic fusion event. This is 
mediated by the SNARE family of proteins. Soluble N-ethyl maleimide sensitive fusion 
protein attachmcnt receptors (SNAREs) have been recogni zed as key components of 
protein complexcs that drive mcmbrane fusion in vesicular transport (Jahn and Scheller, 
2006). One isoform of calpain-I 0 has been shown to associate with the t-SNAREs, 
syntaxin I and SNAP-25 (Marshall el ai., 2005). Furthermore, insulin secretion is 
accompanied by a Ca2+-dependent partial proteolysis of SNAP-25. As both events are 
strongly inhibited by cal pain inhibition, and no other calpain has thus far been found to 
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be assoc iated with SNA P-25, ca l pain- I 0 has been proposed to be a Ca2+-sensor central 
to cxocytosis in B ce lls. 
In B cell s only the 54 kDa isoform of calpain-I 0 has been shown to be associated with 
the cytoskeleton (Turner el ai ., 2007). As this is the same isoform that was shown to 
associate with and cleave the t-SNARE SNAP-25 (Marshall el ai ., 2005), it is tempting 
to speculate that CAPN "j 0 might regulate insulin secretion as part of a single complex at 
the plasma membrane. Support for thi s hypothesis comes from the finding that there is 
dy namic interaction between t-SNAREs and F-actin during glucose-stimulated insulin 
secretion (Thurmond el ai., 2003). There fore, acti vation of thi s one isoform of CAPN 10 
could resu lt in simultaneous actions on both the exocytot ic machinery and the 
cytoskeleton. 
Calpain 10 and Type 2 Diabetes Mellitus 
Cal pain 10 was an unexpected find in the search for a putative diabetes susceptibility 
gene. It s link with diabetes is complex; susceptibility is not attri butable to a single 
variation but to several variations of DNA that interact to either increase, decrease, or 
have no cffect on the risk of developing diabetes. Cal pain lO is an atypical member of 
the cal pa in fam ily, and its biologica l role is unknown. Because CAPN IO mRNA is 
expressed in the pancreas, muscle, and liver, its role in diabetes may involve insulin 
sec retion, insulin action and the production of glucose by the li ver (Horikawa el ai ., 
2002) 
At li rst genome-wide scan studies on 330 sibling pairs identified NIDDM I, the putati ve 
T2DM suscept ibili ty locus, to the region D2S 125- D2S 140 on chromosome 2q37.3 of 
Mexican Americans (Harris el ai., 1996). Four years later positional cloning studies 
revealed that NIDDM I was a single gene, CAPN I 0, and that genetic variation in this 
gene accounted fo r 14% of the population attributable risk to T2DM in this ethnic group 
(Horikawa el ai., 2002). An intronic single nucleotide polymorphism (SNP) in CAPN I 0 
(FIG. 4) was significantly increased in affected individuals but the highest overall risk 
for T2DM was determined by a heterozygous combination of two haplotypes, which 
wcre defi ned by UCSN P43 and two further intronic SN Ps: UCSNP 19 and UCSNP63. 
These high-risk haplotypes are genera lly referred to as " 11 2" (UCSNP43, allele I ; 
UCSNP 19, allele I ; UCSNP63, allele 2) and " 12 1" (UCSNP43, allele I; UCSNPI 9, 
allele 2; UCSNP63 , allele I). This haplotype combination was fo und to confer an overall 
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increased risk ofT2DM in Mexican Americans of2.8-fold, in Botnian Finns of2.S-fold, 
and in Germans of almost 5-fold (Horikawa el aI., 2002). Since this initial work, there 
have been a number of follow-up studies on a diverse range of ethnic populations, which 
e ither confirmed or extended the associations of CAPN I 0 with T2DM (Garant el aI., 
2002) or d isputed the ori ginal findings (Tsai el aI. , 200 I). 
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Figure 4. This fi gure shows the structure of eAPN I 0, the gene encoding human calpain 10 
along with assoc iated SN Ps. The ge ne is located on chromosome and 2q37 .3 compri ses spans 
3 1 Kb of genomic seq uence. The gene contains 15 exons and encodes a protease with a full 
length of 672 amino acid residues. Annotated are UeSN PI 9, UeSN P43, and UeSNP63, 
whi ch are the SNPs that form the risk hap lotypes for T2DM. Along with UeSNP44, which is 
in almost perfect linkage di sequilibrium with the missense coding mutation UeSN PIIO, these 
SN Ps have also been associated with a variety ofT2DM associated phenotypes and disorders. 
(Turner el of. 2005) 
Genetic variations 111 the CAPN I 0 gene at UCSNP43, UCSNP-63 , and haplotype 
combinat ions invo lving these polymorphisll1s along w ith those at UCSNPI9 and 
UCSNP63 have been shown to be associated with elevated free fatty acid leve ls. Studies 
on a Chinese population found that the haplotype combination 11211 2 1 was a potential 
ri sk factor for increased plasma cholesterol while studies on a Japanese population found 
that the UCSN P43 G allele was associated with increased leve ls of plasma cholesterol 
(Daimon el al.. 2002) and increased free fatty ac id levels and dyslipidemia (Sugimoto el 
al.. 2003). 
Similar to the Mexican Americans, the Pima Indians of Arizona had a high prevalence of 
type 2 diabetes. However, in a study among the Pima Indians, no association was found 
between the high-risk genotype SNP-43 GIG and an increased prevalence of diabetes, 
although GIG individuals did have reduced expression of CAPN 10 mRN A and showed 
signs of insulin resistance, which may increase susceptibility to diabetes (Baier e/ 01., 
2007). 
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In Europe, CAPN I 0 appears to contribute less to T2DM. In Britain, there was no 
association between SNP-43, SNP-19, and SNP-63 and diabetes, but it is possible that 
SNPs at other sites in the calpain gene may increase T2DM risk (Evans et aI., 200 1). In a 
large study in Scandinavians, no association was found between these three SNPs and 
diabetes (Rasmussen et aI., 2002). In Asia, genetic variation in CAPN I 0 did not 
contribute to diabetes in Japan (Horikawa et al., 2003) or in the Samoans of Polynesia 
(Tsai el aI., 200 I), although variations of CAPN I 0 may playa role in the risk of diabetes 
in the Chinese (Wang et aI., 2002). 
Obesity is a key determinant in diabetes development, with increased lipolysis from the 
increased fa t ce ll mass being suggested to lead to the development of skeletal muscle 
insulin resistance (Beck-Nielsen and Groop, 1994; Boden, 1997). Geneti c variations in 
the CAPN I 0 gene at SNP-43, SNP-63 and the haplotype combination SNP-44/431l9/63 
112111121 have been shown to be associated with elevated free fatty acid levels and 
insulin resi stance in a Fitmish population (Orho-Melander el ai., 2002). They found that 
fasting FFA levels were significantly higher in carriers of the SNP-43 genotypes II or 12 
compared to genotype 22 carriers . This difference was evident across both sexes in 
patients with type 2diabetes as well as in normoglycemic individuals. Mildly obese 
individuals with the SNP-43 GIG genotype have been shown to have both elevated 
triglyce ride levels and reduced adipose tissue CAPN I 0 mRNA levels (Carlsson et ai., 
2004). The effect of insulin to stimulate glucose uptake into peripheral tissues is essential 
for the maintenance of normal glucose homeostasis (Cushman and Wardzala, 1980). 
Impaired glucose uptake into skeletal muscle and adipose tissue is a major feature of 
T2DM (Rothman et al., 1992). One of the important rate-limiting steps for insulin action 
that has been found to be impaired in T2DM is that of glucose transport mediated by the 
glucose trallsporter-4 (GLUT4) (Cline et aI., 1999). GLUT4 is normally translocated 
from an intracellular pool to the plasma membrane in response to insulin (Watson et aI., 
2004), but inhibition of calpain act ivity has been shown to cause a reduction in insulin-
stimulated glucose uptake into isolated rat muscle strips and adipocytes (Sreenan et aI., 
200 1). Overexpression of the calpain inhibitor calpastatin in skeletal muscle leads to an 
intracellular accumulation of GLUT4, but with no concomitant increase in transporter at 
the plasma membrane or upregulation of glucose metabolism (Otani et ai., 2004). 
CA PN I 0 gcne polymorph isms have been found to correlate wi th several aspects of 
insulin secretion (Lynn el ai., 2002). Genetic variation in the CAPN IO gene accounted 
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for 14% of the population attributable risk to T20M in Mexican Americans, with the 
common G allele of an intronic SNP, UCSNP-43, significantly increased in affected 
subjects (Oda el al., 2000). In Mexican American, the frequency of the common SNP-43 
allele I was significantly higher in the patient group than that in random sample 
(Horikawa el aI., 2000). The most common diplotype of SNP-43, -19, and -63 observed 
in Mexican Americans wi th T20M was 11 2112 1, which was associated with a 2.80-fold 
increased risk of diabe tcs (95% CI, 1.23- 6.34) (Horikawa el aI. , 2000), whereas thi s was 
2.55 and 4.97 fo ld in Botnian Finns and Germans respecti ve ly (Oda el aI. , 2000). In a 
study in Northern Sweden, this c1u'omosomal region was also demonstrated to be linked 
to diabetes while there was no association of the variations in CAPN I 0 gene 
(Ei narsdottir el aI., 2006). 
Other variants apart from UCSNP-43 may have a role in determining disease 
susceptibility. The UCSNP-43 association with T20M appears so far to be almost unique 
to Mcxican Amcricans (Oda el . a/., 2000), whereas UCSNP-44 may dictate an 
underlying low level ri sk across many ethnic groups (Weedon el al., 2003). [n contrast, 
the UCSNP-63 variant was more important for disease association in both Botnian Finns 
and South Indians (Cassell el ai., 2002) but not in Mexican Americans. In addition, a 
borderline association was detected with the UCSNP-63 locus when family data was 
pooled (Song el ai., 2004). Furthermore, analysis of the South Indian data using a novel 
stati stical approach suggested that the UCSNP-1 9 genotype may add itionally contribute 
10 the disease susceptibility wi thin thi s ethn ic group and obes ity in Europeans (Hoffstedt 
('la/. , 2002). 
A study of non-diabetic German subjects showed that SNP-43 was associated with 
increased insulin secretion and proinsulin processing (Stumvo ll el 01., 200 1). 
Polymorphism at SNP-44 has been shown to alter the shape of the plasma glucose curve 
during oral glucose tolerance test (Tschritter et 01., 2003), ind icati ve of di sease 
association. 
Vari ation in CAPNIO gene has similarl y been associated with quantitative traits re lated 
to diabetes. Thus, the SNP43 has in some studies been related to fasting and post-oral 
glucose tolerance test (OGTT) plasma glucose levels (Lynn et ai. , 2002) and other 
investi gators have reported associations with di fferent estimates of insulin resistance and 
insulin secretion (Orho-Melander el al., 2002). A genotype combination of 
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SNP43/SNP44 GGrrT has been reported to associate with elevated fasting serum 
cholesterol levels (Daimon et aI., 2002), whereas SNP43 alone was associated with 
elevated fasting serum triglyceride levels in obese subjects (Carlsson et al., 2004). 
Association of the CAPN I 0 SNPs and obesity has been reported In one study 
(Pihlajamaki el al., 2006), whereas no association with obesity has been found in other 
studies (Carlsson et aI. , 2004). 
Another study found that haplotype combination 111 / 121 ofCAPNIO was related (Kang 
el al., 2006) with an increased risk of metabolic syndrome in patients with T2DM. These 
results suggest that the genotype combination SNP-43, -19, and -63 is a risk factor for 
metabolic syndrome. Intronic variation in CAPN I 0 was associated with elevated 
trigl yceride levels and reduced adipose ti ssue mRNA expression (Carl sson el al. , 2004) 
in morbidly obese Swedish subjects, suggesting that a low CAPN I 0 gene expression 
might be a risk factor for conditions related to the metabolic syndrome. Taking these data 
together, it appears that polymorphisms of CAPN 10 gene do influence susceptibility to 
T2DM and insulin resistance across populations of different racial backgrounds. The 
strength of thi s influence does seem to differ between populations. Some of these studies 
have been shown with a modest increase in risk to T2DM due to the CAPN I 0 gene. 
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HYPOTH ESIS 
CAPN 10 gelle SN P 44 T>C polymorphic IS not associated with type 2 diabetes 111 
Bangladeshi populati on. 
OBJECTIVES 
Generalobj ecis 
The general objective of the present stud y was to determine CAPN 10 gene SN P 44 T>C 
var iant in T DM patients of Bangladeshi ori gin to explore in assoc iati on with insulin 
secretory capacity and insulin sensiti vity. 
S, I<'ci/ic ol, jeclives 
Til e speci fic objecti ves of the present study were to: 
• To determine CA PN 10 gene SNP 44 (T>C) in the TDM subjects of Bangladeshi 
ori gin. 
• To measure the insulin level of the T DM su bjects and association their secretory 
capacity and insulin sensiti vi ty. 
• To explore the relati onshi p, if any, between CAPN 10 SN P 44 T>C po lymorphi sm 
and ofl he T2DM subj ects. 
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Chapter 3 
SUBJECTS & METHODS 
SUBJECTS AND METHODS 
Place of the study 
The study was conducted in the laboratory of Biomedical Research Group (BMRG), 
Research Division, Bangladesh Institute of Research and Rehabilitation in Diabetes, 
Endocrine and Metabolic Disorders (BlRDEM), Dhaka, Bangladesh. 
Study period 
This study was done during the period of June 2009 to March 20 I o. 
Study design 
This was a case control study. CArN 1 0 SNP-44 T>C polymorphic marker was taken as 
the exposure factor. 
Subjects 
A totalnul11ber of 156 (One hundred and fifty six) subjects were purposive ly recruited in 
the study irrespectively of race, religion and socioeconomic status. Diabetes was 
diagnosed following WHO criteria (WHO 1999). Of the total 91 subjects were 
healthy control and 65 type 2 diabetes mellitus (T2DM) subjects. 
Development of Questionnaire 
A predesigned case record form was used to document detail medical records, 
anthropomctric measurements (Appendix f). Diabetic patients were recruited from the 
Out-patient department (OPD), BIRDEM. Control subj ects were recruited from the 
community through personal communication. 
Purpose and method of the study was briefed to each individual and informed 
consent (Appendix If) was obtained. 
Collection of the subjects 
Subjects were collected on every working day of the week in the laboratory of 
BMRG, BlRDEM. Subjects recruited through personal communication from the 
community. Subjects willing to have blood glucose check were also invited to volunteer 
the study. They were advised to be on their usual diet for 3 days and requested to 
report BMRG Lab between 8.00-10.00 am in fasting state (8-10 hours). 
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Selection Criteria 
In elusion Criteria 
• Healthy subjects with age range 30 to 60 years. 
• Vo luntarily agreed to participate in thi s study. 
Exclusion criteria 
• Subjects with co-morbid diseases (infection, stroke, myocardial infarction, major 
surgery, essential hypertension, malabsorption etc.). 
• History of using drugs which may significantly affect glucose metabolism 
(glucocorticoids, high-dose estrogen, phenytoin, high-dose thiazide diuretics etc.). 
• Pregnancy. 
Anthropometric mcasuremcnts 
Height (m) 
Standing height was measured using appropriate scales (Detect-Medic, Detect scales 
fNC, USA) following standard procedure. Height was recorded to the nearest 5 mm. 
Weight (kg) 
The balance was placed on a hard fl at surface and checked for zero balance before 
measurement. The subjects were in the center of the platform wearing light cloths 
without shoes. Weight was recorded to the nearest 0.5 kg. 
Calculation of BMf (kg/1I12) 
Body mass indexes (BMI) of the subjects were calculated using fo llowing formula 
MAC (cm) 
BM I Weight (kg) 
[Height (m)] 2 
Mid Upper Arm Circumference (MAC) was measured at a point mid way between the 
acromial process of scapula and olecranon process of ulna of ri ght arm hanging relaxed. 
A measuring tape was used to record the circumference following the above technique at 
the nearest millimeter. 
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Waist circlllliferellce (cm) 
Waist circumference was measured to the nearest 0.5 cm with a soft non-elastic 
measuring tape. The tape was snug, but not so tight as to cause skin indentation or 
pinching. The waist circumference was taken to the nearest standing horizontal 
circumference between the lower border of the 12th rib and the highest point of the iliac 
crest on the mid-axillary line at the end of normal expiration. 
Skill fold thicklless (mm) 
Skin fold thickness was measured using I-larpenden Skin fold Calipers. Triceps skin fold 
thickness was measured I cm above the mid point between the acromial process of 
scapula and olecranon process of ulna at mid-line posteriorly with skin fold lying along 
the long axis of right arm hanging relaxed. Subscapular skin fold thickness was 
measured I cm bellow the inferior angle of right scapula with skin fo ld lying at 45 
degree. Values were recorded at the nearest millimeter. 
Body fat mass (%) 
Body fat mass was measured by Omron Body Fat Monitor (Model HBF-302). Height in 
cm, weight in kg, age in yrs and gender at the individuals enter to the body fat monitor. 
The subjects were asked to hold the monitor by both hands with upper limbs horizontal 
in standing position. The machine was then initiated and body fat mass (%) calculated by 
the unit was flashed on the display screen and value was recorded. 
Measurement of blood pressure 
Blood pressmc was measured in sitting position, with calf at the level of the heart. After 
10 minutes of rest a second reading was taken. Recorded Korotkoff sound I (the first 
sound) and V (the disappearance of sound) denoted the systolic blood pressure (SBP) 
and diastolic blood pressure (DBP), respectively (according to WHO-IHS). 
METHODS 
Collectioll of blood samples 
Overnight fasting (8-10 hours) blood was collected between 8.00-9.00 am. Venous blood 
(10 ml) was obtained by venepuncture following standard procedure. Subjects were then 
given glucose to drink (75 g in 300 ml of water) . They were requested not to take any 
food and be rested for two hours. The second blood sample was then obtained. 
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A portion of blood (5 ml) sample was taken into a tube containing EDTA (I mg/ml), 
mixed tboroughly and preserved in at _30°C for future DNA extraction and subsequent 
experimentation. Fasting and postprandial blood sample were taken into plain tube 
allowed to clot for 30 minutes and serum was separated by centrifugation for \0 min at 
3000 rpm using refrigerated centrifuge and preserved at _25°C for furtber biochemical 
analyses. 
Biochemical methods 
Estimation of Glucose 
Glucose was estimated by enzymatic colorimetric (GOD-PAP) metbod in tbe Hitachi 
704 Automatic Analyzer, Hitachi Ltd., Tokyo, Japan using reagents of RANDOX 
Laboratories Ltd., UK. 
Principle 
Glucose is determined after enzymatic oxidation in tbe presence of glucose oxidase. The 
hydrogen peroxide formed reacts witb phenol and 4-arninophenazone under catalysis of 
peroxidase to form a red violet quinoneimine dye as indicator (Trinder, 1969). 
Glucose 
Glucose + H20 Oxidase I Gluconic acid + H20 2 
2H20 2 + 4-aminophenazone + phenol Peroxidase I Quinoneimine + 4H20 
Reagents 
Contents Initial concentration ofsolution 
Phosphate Buffer 0.1 molll, pH 7.0 
Phenol 11 molll 
4-arninophenazone 0.77 mmolll 
Glucose oxidase ~1.5 kU/I 
Peroxidase ~1.5 kU/I 
Glucose Standard 5.55 mmolll (100 mg/dl) 
Uranyl Acetate 0.16% 
?Q 
Procedure 
The method detennines glucose without deproteinization. The instrument was calibrated 
before estimation. Serum and reagent were taken in specific cup. They were arranged 
serially into the Auto analyzer. The Auto analyzer was programmed for the estimation of 
glucose and allowed to run with following procedure: 
5 ~l sample and 500 ~l reagent were mixed and incubated at 37° C for 10 minutes. The 
reaction occurred in reaction cell or cup. The absorbance of the sample and the standard 
against the reagent blank were measured at 500 nm within 60 minutes. 
Calculation of the result 
Optical densities or absorbances were fed into a computer and calculation was done 
using the software program. Values for the unknown samples were calculated by 
extrapolating the absorbance for the standard using following fonnula. 
ASample 
Glucoseconcentration (mmol/l) = x 5.55 
A Sta,wrd 
Estimation of Total Cholesterol 
Total cholesterol was measured by enzymatic endpoint method (cholesterol 
OxidaselPeroxidase) method in auto analyzer Auto analyzer HITACHI 704, Hitachi Ltd 
Tokyo, Japan. 
Principle 
The cholesterol was determined after enzymatic hydrolysis and oxidation. The indicator 
quinoneimine is fonned from hydrogen peroxide and 4-aminoantiphyrine in the presence 
of phenol and peroxidase (Richmond, 1973). 
Cholesterol ester + H20 
Cholesterol + O2 
Cholesterol 
--,E:::s:.:;te:.:.r.=as::.:e,--~) Cholesterol + Fatty acids 
Cholesterol 
Oxidase Cholestene- 3-one + H20 2 
2H20 2 +phenol+4-aminoantiphyrine Peroxidase l Quinoneimine + H20 
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Reagents 
Contents Initial Concentration of Solution 
4-Aminoantipyrine 0.30 mmolll 
Phenol 6 mmolll 
Peroxidase ~ 0.5 Ulml 
Cholesterol esterase ~ 0.15U1ml 
Cholesterol oxides ~0.1 Ulml 
Pipes Buffer 80 mmolll; pH 6.8 
Standard 5.17 mmolll (200 mg/dl) 
Procedure 
Serum and reagents were taken in specific cup or cell. They were arranged serially. Then 
ill number for each test was entered in the Auto analyzer. 5 iii sample and 500 iii reagent 
were mixed and incubated at 37°C for 5 minutes within the Auto lab. The reaction 
occurred in reaction cell or cup. The absorbance of the sample and the standard against 
the reagent blank were measured at 500 nm within 60 minutes. 
Calculation of result 
Concentration of cholesterol in sample was calculated by using software program with 
the following formula. 
ASample 
Cholesterol concentration (mg/dl) = A S/Qndord x concentration of standard. 
Estimation of Triglyceride 
Triglyceride was measured by enzymatic colorimetric (GPO-PAP) method in the Hitachi 
704 Automatic Analyzer, Hitachi Ltd., Tokyo, Japan using reagents of RANDOX 
Laboratories Ltd., UK. 
Principle 
The triglyceride is detennined after enzymatic hydrolysis with lipases. The indicator is a 
quinoneimine formed from hydrogen- peroxide, 4- aminophenazone and 4-chlorophenol 
under the catalytic influence of peroxidase (Fossati and Prencipe, 1982). 
Triglyceride + H20 Lipase, Glycerol + Fatty acids 
GI)'Cerol 
Glycerol + ATP Kinase, Glycerol-3-phosphate + ADP 
Glycerol 
Phosphote 
Oxidase Glycerol-3-phosphate +0, --""""'''''-->, Dihydroxy acetone phosphate + H20 2 
Peroxidase Quinoneimine + HCI +4H20 
2H,0, + 4-aminoohenazone +4- chloroohenol ---'-"'-"''''''''",-+, 
Reagents 
Contents Concentrations in the Test 
Buffer 
Pipes Buffer 40 mmolll, pH 7.6 
4-choloro-phenol 5.5 mmol/l 
Magnesium-ions 17.5 mmol/I 
Enzyme Reagent 
4-aminophenazone 0.5 mmolll 
ATP 1.0 mmoVI 
Lipases >150 V/ml 
Glycerol-3-phosphate oxidase 1.5 V/ml 
Peroxidase 0.5 V/ml 
Standard 2.29 mmoVI (200 mg/dl) 
Procedure 
Serum and reagents were taken in specific cup. They were arranged serially. Then ID 
number for test was entered in the analyzer. Five (5) J.lI sample and 500 J.lI reagent were 
mixed and incubated at 37°C for 5 minutes within the cell. Reading was taken at 500 DID. 
Calculation of result 
Triglyceride concentration was calculated by following formula: 
ASampk 
Triglyceride concentration (mgldl) = x Concentration of standard. 
A S1andard 
Estimation of high density lipoprotein (HDL) cholesterol 
High density lipoprotein cholesterol (HDLc) was measured by enzymatic colometric 
method using reagent of Randox laboratories, UK. 
Principle 
HDL (High Density Lipoproteins) is separated from 'chylomicrons, VLDL (very low 
density lipoproteins) and LDL (Low density lipoproteins) by precipitating reagent 
(phosphotungstic acid-magnesium chloride). After centrifugation, the cholesterol 
contents of HDL fraction, which remains in the supernatant, was determined by the 
enzymatic colorimetric method using CHOD- PAP (Friedwald el aI. , 1972). 
Materials and reagents 
I. Precipitant Buffer 
2. Lipid Controls 
3. Randox aqueous Cholesterol Standard: 200 mgldl 
4. Reagent solution for cholesterol CHOP-PAP assay. 
5. Pipettes (5 fll-50 fll, 100 fll-lOOO fll) and Pipette Tips. 
6. Multi-Channel Pipettes and Pipette Tips: 50-300 J.lI 
7. Buffer and Reagent Reservoirs 
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8. Vortex Mixture 
9. Deionized Water 
10. Microtiter Plate Reader capable of reading absorbency at 450 nm 590 run 
II. Orbital Microtiter Plate Shaker 
12. Absorbant Paper 
Reagents composition 
Phosphotungstic Acid: 0.55 mmol/l 
Magnesium Chloride: 25 mmolll 
Stal/dard Preparatiol/ 
Di lute Randox aqueous cholesterol standard (200mg/dl) with deionized water by volume 
of 0,20,40,50, and I 00 ~l. The final volume was 200 ~l. 
ASSllY Procedllre 
I . 100 ml serum samples taken in microcentrifuge tube 
2. Add 250 ~I HDL-c Precipitant. 
3. Mix well and allow sitting for 10 minutes 
4. Vortex the mix components and centrifuged for IS minutes at 4000 rpm. 
5. Transfer 30 ~I of each Standard in first six wells. 
6. Transfer 30 ~I of clear supernatant into the other we ll s 
7. 250 ~I of cholesterol reagent was then added into all the 96 wells quickly 
using multi-channel pipettes. 
8. Incubated for 5 minutes at 37°C on orbital microtiter plate shaker. 
9. Absorbance was read at 490 nm. 
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Calclllatioll 
The HDL-c value of each sample was obtained as follows: 
The net absorbance value for each level obtained, by subtracting the value for the HDL-c 
concentration (mgldl) from the value of individual. The smooth linear curve was drawn 
and the results of unknown samples were calculated using logistic function. 
Estimation of LDL-cholesterol 
The LDL-Cholesterol level 111 serum was calculated by using by Friedewald formula 
(Fri edwald el aI. , 1972). 
Formula 
LDL cholesterol = {Total cholesterol- (HDL Cholesterol + 
Estimation of Creatinine 
I 
-x 
5 
Triglyceride)} 
Estimation of creatinine was done by alkaline-picrate methods uSing reagents from 
Randox Laboratories, UK. 
Prillciple 
Creatinine in alkaline so lution reacts with picric acid to form a colored complex. The 
amount of the complex formed is directly proportional (0 the Creatinine concentration 
Sample: Serum. 
Reagellts 
Standard 177umol/ l (2mgldl) 
Picric acid surfactant 35 mmol/L 
Sodium hydrox ide 0.32 mollL 
Preparatioll of reagellt 
All reagents are supplied ready to use, stable to expiry date when stored at + IS to 250C. 
Preparatioll of workillg reagellt 
Mix Equal volumes of Solutions 2+3, Stable for 3 Days At + 15 to+250C. 
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Procedure 
Wavelength 
Cuvette 
Temperature 
Measurement 
Pipette into cuvette 
Working reagent 
Standard solutions 
Sample 
Standard 
1.0 ml 
0.1 ml 
492 (490-510) nun 
1 Cm Light Path 
25/30/37 C 
against Air 
Sample 
1.0 ml 
0.1m! 
Mix and after 30 sec, read the absorbance Al of the standard and sample Exactly 2 min. 
later read the absorbance A2 of the standard and sample 
Calculation 
A2-AI = M sample or M standard 
Concentration of Creatinine in Serum (mg/d!) 
Estimation of SGPT 
D.A sample 
______ Xl00 
Mstandard 
SGPT was estimated by UV method using AL T (GPT) opt. kit (RANDOX) (!FCC, 
1980). 
Principle 
AL 
(X- oxogluterate + L - alanine ---_~ L-glutamate + pyruvate 
Pyruvate + NADH + W _...::L::::D:::...-_~ L-Iactate + NAD+ 
Reagellts 
Contents 
I. Buffer/Substrate 
Tris biffer 
L-alanine 
2. Enzyme/Coenzyme/a-oxoglutarate 
a-oxoglutarate 
LD 
NADH 
Preparatioll of So/utiolls 
Concentration in the test 
100 mmol/ I, pH 7.5 
0.6 molll 
15 mmol/l 
2: 1.2 Ulml 
0.18 mmol/l 
I . BufferlSubstrate: Buffer/Substrate suppl ied in the kit was used as it is. 
2. Enzyme/Coenzyme/a -oxoglutarate: One vial of Enzyme/Coenzyme/ll-oxoglutarate2 
was reconstituted with the appropriate volume of BufferlSubstrate I : 
2ml for the 
10ml for the 
20ml for the 
Cat No AL 2360 5 x 1001111 
20 x 
20 x 
5x 
2 ml kit CAL 1200) 
10 ml kit CAL 1205) 
20 ml kit CAL 1268) 
One vial of Enzyme/Coenzyme/a-oxoglutarate 2 was reconstituted with a portion of 
BufferlSubstrate I and then the entire content was transferred to bottl e I rinsing bottle 2 
several times. 
Procedure 
Wavelength: 
Cuvette: 
Temperature: 
340 run CHg 334 nm or Hg 365 nm) 
I em light path 
25/30/37°C 
37 
Measurement: 
Pipetted into cuvette: 
Serum 
Enzymc/Coenzymela-oxog lu-taratc 2 
against air 
Macro 
0.2 ml 
2.0 ml 
Micro 
0.1 ml 
1.0 ml 
Mixed and initial absorbance was read after I minute. Again after I, 2 and 3 minutes the 
absorbance was read. The absorbance change per minute was noted and if the value is 
between: 
0. 1 I and 0. 16 at 340 nm/Hg 340 nm 
0.06 and 0.08 at Hg 365 Ill1 
Only then the values for the first 2 minutes were used for the calculation. 
ClI/CII/lIliOIl 
To calculate the ALT activi ty the following formulae was used: 
U/I 1746 x 6.A 340 IUnlmin 
UII 1780 x 6.A Hg 334 I1mlmin 
UII = 3235 x 6.A Hg 365 IUnlmin 
Normll/ vlIllles ill serum 
Men 
Women 
25°C 
Up to 22 UII 
Up to 17 U/I 
30°C 
Up to 29 U/I 
Up to 22 UII 
37°C 
Up to 40 UII 
Up to 31 U/I 
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Lillearity 
If the absorbance change per minute exceeds 
0.16 at 340 nm/Hg 334 nm 
0.08 at Hg 365 lun 
0.1 ml of sample was diluted with 0.9 ml pf 0.9% NaCI solution and reassessed. The 
result was multiplied by 10. 
Estimation of insulin 
Insulin by enzyme linked immunosorbent assay (ELISA) method using kit from Linco 
Research Inc., USA. 
Prillciple 
This assay is a sandwich ELISA based, sequentially, on: 1) concurrent capture of human 
insulin molecules from samples to the wells of a microtiter plate coated by a pre-titered 
amount of monoclonal anti-human insulin antibodies and the binding of a second 
biotinylated monoclonal mouse anti- antibody to the captured insulin, 2) washing of 
unbound materials 3) binding of horseradish peroxidase to the immobilized biotinylated 
antibodies, 4) washing of free enzyme conjugates, and 5) quantification of immobilized 
antibody-enzyme conjugates by monitoring horseradish peroxidase activities in the 
presence of the substrate 3,3',5,5'-tetramethylbenzidine. The enzyme activity is 
measured spectrophotometrically by the increased absorbance at 450 nm after 
ac idification of formed products. Since the increase in absorbance is directly proportional 
to the amount of captured human insulin in the unknown sample, the latter can be 
derived by interpolation from a reference curve generated in the same assay with 
reference standards of known concentrations of human insulin. 
Reagellts supplied 
Each kit was sufficient to run one 96-well plate and contains the following reagents: 
I . Microtiter plate: Coated with mouse monoclonal anti-human insulin antibodies. 
2. Adhesive plate sealer 
3. lOX concentrate HRP wash buffer (2x50ml). 
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4. Standards: Human insulin in buffer 2, 5, 10,20, 50, 100 and 200 flU/ml; 0.5 mllbottle, 
ready to use. 
S. Quality Controls I and 2: Purified recombinant human insulin in assay buffer, ready to 
use. 
6. Matrix Solution: Heat-treated charcoal stripped off the clot human insulin serum (2x I 
ml), ready to use. 
7. Assay Buffer: 0.05 M Phosphosaline, pH 7.4, containing 0 .025 M EDTA, 0.08% 
Sodium azide, 1% BSA, 2x9 ml, ready for use. 
8. Human insulin detection antibody: Pre-titered biotinylated monoclonal mouse anti-
hwnan insulin antibody (2x12 ml), ready to use. 
9. Enzyme so lution: Pre-titered streptavidin-horseradish peroxidase. Conjugation Buffer 
(2x 12 ml ), ready to use. 
10. Substrate: 3,3 ',5,5'-tetramethylbenzidine in buffer (12 ml), ready to use. Minimize 
exposure to light. 
II. Stop solution: 0.3 M HCl (12 ml), ready to use. 
Malerittfs required 
I . Pipettes and pipette tips: 10 fll - 20 ~tl or 20 fll-I 00 fll 
2. Multi-channel pipettes: 5- 50 fll and 50- 300 fll 
3. Reagent reservoirs 
4. Vortex mixture 
5. Deionized water 
6. Microtiter plate reader capable of reading absorbency at 450 nm 590 nm 
7. Orbitalmicrotiter plate shaker 
8. Absorbant paper 
9. Standard refrigerator 
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Reagellt preparatioll 
I-IRP Wash Buffe r: Diluted l OX I-IRP washing buffer concentrate 10 fold by mixing the 
entil"e content of each bottle with 450 ml deionized water. 
Storage alld Stability 
All components of the kit were stored at 2_80 C. Multiple freeze/thaw cycles of the 
insulin standards and Matrix solution were avoided. 
Assay Procedllre 
I . The reagents were allowed to come to room temperature. Then each well filled 
with 300lli of diluted I-IRP wash buffer and incubated at room temperature for 5 
minutes. Then wash buffer was decanted and the residual amount was removed 
fro m all we ll s by inverting the plate and tapping it smartly onto the absorbent 
towels several times. 
2. The microtitre plate was maJ"ked. A layout of the plate for blank, standards, QCs 
and unknown samples were made and recorded on a paper. 
3. 20 ~t1 assay buffer was added to the NSB (Non Specific Binding) wells and each of 
the sample wells. 
4. 20 III matrix solution was added to the NSB, Standard and Control wells. 
5. 20 III human insulin standard in the order of ascending concentration was added to 
the appropriate well s. 
6. 20 III of QC I and QC 2 was added to the appropriate wells. 
7. Then 20 III of unknown samples were added sequentially in wells according to the 
plate layout. 
8. After that 20 ~" of detection antibody was added to all wells. All procedures were 
perfo rmed within 30 minutes. Plates were covered using plate sealer and incubated 
at room temperature for I hOllr on an orbital microtitre plate shaker to rotate at 
moderate speed approximately 400 rpm. 
9. At the end of incubation, plate sealer was removed and solutions were decanted. 
Residual solutions were removed by tapping as b'efore. Each wells was then 
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washed for 3 times with 300 III diluted HRP wash buffer. After each wash the plate 
was tapped on a pad of ti ssue to dry it off. 
10. I 00 ~d of enzyme solution was added to each well using a multichannel pipette. 
Plates were covered with sealer and incubated again with moderate shaking at room 
temperature for 30 minutes on microtitre plate shaker. 
II. Then sealer was removed and solutions were decanted from the plate and tapped to 
remove the residual fluid. Then wells were washed for 5 times using 300 III HRP 
wash buffer per well per wash and after each wash the plate was tapped smartly to 
remove the residual buffer. 
12. 100 III of substrate solution was added to each well and covered with sealer and 
incubated with moderate shaking at room temperature for 10 minutes on microtitre 
plate shaker. Blue color was formed in the wells of insulin standards with intensity 
proportional to increasing concentrations of insulin. 
13. Finally sealer was removed and 100111 of stop solution was added. Plate was placed 
on a microtitrc plate shaker for gentle shaking (400 rpm). 
14. Reading was taken using a microplate reader at 450 nm. 
Calculatioll of results for UllkllOlV1I samples 
Optical densities of standard and unknown samples were fed in to a computer 
programme. A result of unknown samples was calculated extrapolating standard four 
parameter logistic curves using a Software Kinetical 3. 
Determination of insulin secretory capacity and insulin sensitivity 
Homeostasis Model Assessment (HOMA%S) is a simple widely used method which 
derives separate indices of B cell secretion (HOMA%B) and insulin sensitivity 
(HOM A % S) from the serum glucose and insulin concentrations under basal conditions 
by using mathematical formula or software (Levy el ai. , 1998). The HOMA model has 
been incorporated in a simple MS-DOS-based computer program (HOMA-CIGMA 
software) that allows rapid determination of % B (B cell secretion) and % S (insulin 
sensitivity) from measured values. Although the simple equation gives a qualitatively 
useful approximation of the model prediction, most a!lthors prefer the computer model. 
In thi s study HOMA-CIGMA software was used. 
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DNA extraction 
Extraction of DNA was performed using GenElute DNA extraction kit (Q1AGEN, USA). 
The kit uses the principal of silica gel DNA isolation from whole blood adapted in spin 
column. 
Eqllipment, reagent allli accessories 
• Wuter bath 
• Vortex 
• Centrifuge 
• Microcentrifuge tubes (1.5 ml) 
• Pipette tips at different capacities (10 fll, 20 fll , 100 fll, 200 fll and 1000 fll) 
• Micropipettes (4-50 ~d , 100-1000 fll) 
• Absolute ethanol (95-100 %) 
Content of DNA kit 
• Extraction column 
• Collection tubes 
• Proteinase K 
• RNase-A solution 
• Lyses Buffer AL 
• Wash Buffer A WI 
• Pre-Wash Buffer A W2 
• Elution Buffer AE 
Preparation of reagellts 
Wash buffer AWl: 125 ml ethanol (96-100%) was added to obtain 125 ml Buffer AWl 
(95 ml concentrated). 
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Wash burrel' A W2: 160 ml ethanol (96-100%) was added to obtain 226 ml Buffer A W2 
(66 ml concentrated). 
Extractioll procedllre 
1. Frozen blood was brought to room temperature and made homogenous by brief 
vortexing. Aliquot of blood (200 Ill) was transferred into 1.5 ml microcenlrifuge 
tube. 
2. 20 III QIAGEN proteinase K was added inside the cap of the microcentrifuge tube . 
3. 4 III of an RNase-A stock solution (IOOmg/ml) was added to the sample before 
adding of Buffer AL. 
4. 200 ~d Buffer AL was added to the sample. In order to ensure efficient lyses, pulse-
vortexed for IS sec to make a homogenous so lution. 
5. Incubated at 56°C for 10 min. 
6. To remove drops from the inside of the lid at the tube briefly centrifuged. 
7. 200 ~d ethano l (96-100%) was added to the sample, and mixed by pulse-vortexing 
for 15 sec and brielly spanned. 
8. The mixture from the step 7 was transferred to the QIAamp Mini Spin Column 
(mounted on 2 1111 collection tube) without wett ing the rim and after closing the 
cap, centrifuged at 6000 x g for I min. The QIAamp Mini Spin column was placed 
on a fresh 2 ml co llection tube. 
9. The QIAamp Mini Spin column was opened carefully and 500 III Buffer AW l was 
added without welting the rim. Centrifuged at 6000 x g for I min. the collection 
tube was discarded and the spin column was placed on fresh collection tube. 
10. The QIAamp Mini Spin column was opened carefully and 500 III Buffer A W2 was 
added without wetting the rim. Cap was screwed carefully and the centrifuged at 
20000 x g for 3 minutes. At this stage the column appeared to be clean. 
11. The QIAamp Mini spin column placed again on a 2 ml collection tube. 200 III 
Buffer AE was added to the column. Incubated at room temperature for 5 minutes. 
Centrifuged at 6000 x g for I minute at 25°C. This elute supposed to contain DNA. 
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CfleckJor DNA extractioll 
DNA yield for each sample was checked by agarose gel (1%) electrophoresis. To prepare 
agarose gel, appropriate amount of agarose was taken into polypropylene conical flasks 
containing required volume of working tris-borate EDT A (TBE) buffer. Agarose and 
buffer so lution was mixed by swirling of the flasks. It was then heated to boiling point in 
a microwave oven with intermittent mixing until agarose was properly boiled. The gel 
was cooled nearer to the gelling point and ethidium bromide (O.51lg/ml) was added. The 
gel was then poured into horizontal gel mould, combs inserted, and allowed to 
polymerize. The gel was subsequently placed in horizontal electrophoresis tank filled 
with working TBE buffer. 
To resolve DNA extract 3 ~d of DNA elute mixed with appropriate amount of loading 
buffer and then the mixer was loaded in agarose gel prepared earlier. The gel was run for 
at medium voltage for required time. DNA presence was visualized under UV light and 
gel image was captured. 
Figure 5: Gel image of DNA electrophoresis to check the extraction yield 
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CAPN 10 gene SNP-44 T>C polymorphic marker ana lyses 
Subjects were genotyped for SNP-44 T>C polymorphic marker by a mutagenically 
separated PCR (MS-PCR) method .using a common reverse primer and two allele-
specific forward primers of different lengths. The primers used were as follows: 
Forward primer: 
T allele specitic: 5 '- CAGGGCGCTCACGCTTGCTAT-3' 
C allele specitic: 5 ' -GTGGGCAGAGGACTGGTGGGCGCTCACGCTTGCTTC-3' 
Reverse primer: 5' -CTCA TCCTCACCAAGTCAAGGC-3' 
PCR was carried out in 10 fil reaction volume. Product size for the T allele is 60 bp and 
for C allele is 75 bp. The PCR protocol is as follows: 
Name of the component Volume (fil) Concentration 
DNA 5.0 ~Ll 10-50 nglml 
Buffer 1.00 fi l lOX 
dNTPs 0.10 fil 200 fimol 
Forward Primer (T) 1.00 fil 10 fimol 
(C) 0.067fil 10 fimol 
Reverse Primer 1.00 fil 10 fimol 
HotStart Tag DNA polymerase 0.08 fil 5U1fil 
1.753~Ll 
Total 10.0 III 
peR cOllditiollS 
PCR was carried out using HotStart Tag polymerase. Conditions for the amplification of 
the above mention product include initial step of denaturation 95°C for 15 min followed 
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by 34 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds 
and elongation at noc for 30 seconds and the 34th cycle was followed by a step of final 
elongation n oc for 10 minutes. 
The peR products were resolved In 3% agarose gel and visualized uS1l1g gel 
documentation system following ethidium bromide straining. The PCR products were 
detected as 60 bp for T allele and 75 bp for C allele. 
75bp 
60bp 
Figure 6: Gel image of PCR products for CAPNIO SNP-44 polymorphic 
marker analysis 
Statistical Methods 
Data were expressed as mean (±SD) and number (percentage) as appropriate. Difference 
between two groups was determined by unpaired Student's 't' test, Chi-square test where 
applicable. Risk for outcome event of candidate gene maker was estimated by Odds 
ratio . Data were managed using stati stical package for social science (SPSS) for 
Windows Vers ion 10. 
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Chapter 4 
RESULTS 
RESULTS 
A total number of 156 unrelated subjects were screened fo r glycemic status. Of them 91 
were healthy controls and 65 were type 2 diabetes mellitus (T2DM). 
Age, BMI and blood prcssure of the study subjects 
Mean (±SD) age (yrs) of the control and T2DM subjects was 41.0±8.0 and 43.0±7.0 
respectively which appeared to be statistically significant different (p=O.058) (Table 2). 
Mean (±SD) body mass index (BMI) of the control and T2DM subjects was 25.9±3.9 
and 24.9±4.0 respectively which did not show statistical significant difference (p=O.163) 
(Table 2). 
Mean (±SD) systo lic blood pressure (SBP, mmHg) of the control and T2DM subjects 
was 112± 12 and 122± 15 respectively which showed statistical significant difference 
(p<O.OO I) (Table 2). 
Mean (±SD) diastolic blood pressure (DBP, mmHg) of the control and T2DM subjects 
was 75.0±7.9 and 77.9±8.8 respectively which showed statistical significant difference 
(p=O.039) (Table 2). 
Mean (±SD) creatinine (mg/dl) of the control and T2DM subjects was O.99±O. 12 and 
O.9S±O.IS respectively which did not show statistical significant difference (p=O.099) 
between the groups (Table 2). 
Mean (±SD) S GPT (U/L) of the control and T2DM subjects was 26.3±14.1 and 
29.3±28.4 respectively which did not show statistical significant difference (p=0.434) 
(Table 2). 
An thropometric mcasurements of the study subjects 
Mean (±SD) mid arm circwnference (MAC, cm) of the control and T2DM subjects was 
29.8±4.2 and 29.2±5.4 respectively which did not show significant difference (p=O.396) 
(Table 3). 
Mean (±SD) triceps skin fo ld (TSr, mm) of the control and T2DM subjects was 
23.17±13.1 and 19.5±9.7 respectively which showed statistically significant difference 
(p=O.064) (Table 3). 
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Mean (±SD) subscapular skin fold thickness (SSF, mm) of the control and T2DM 
subjects was 30.8±ll.O and 32.7±IO.9 respectively, which did not show statistical 
significance difference (p=O.291) compared to T2DM (Table 3). 
Mean (±SD) body fat mass (BFM, %) of the control and T2DM subjects was 30.0±6.6 
and 28.5±6.5 respectively which did not show significant difference (p=O.161) (Table 3). 
Mean (±SD) waist hip ratio (WHR) of the control and T2DM subjects was O.92±O.06 and 
O.94±O.06 respectively. WHR value of T2DM group was significantly higher compared 
to the controls (p=O.083) (Table 3). 
Serum glucose levels and insulinemic status of the study subjects 
Mean (±SD) fasting serum glucose (FSG, mmolll) of the control and T2DM subjects was 
5.0±O.6 and 8.0±3.8 respectively. Mean (±SD) postprandial glucose (PPG, mmol/l) of 
control and T2DM subjects was 5.8±1.l and 15.3±4.9 respectively (Table 4). 
Mean (±SD) fasting serum insulin (flU/ml) in the control and T2DM subjects was 
IO.5±5.3 and 17.2±IO.9 respectively. Mean serum insulin in the T2DM group was 
significantly higher compared to tile Controls (p<O.OOI) (Table 4). 
Mean (±SD) of HOMA %B in the Control and T2DM subjects was 115.0±52.0 and 
99.8±57.3 respectively. Mean HOMA%B values did not show any statistically 
significant difference between the groups (p=O.176) (Table 4). 
Mean (±SD) HOMA% S values in the control and T2DM subjects was 79.9±20.5 and 
48.9±21.7 respectively. Mean HOMA%S value in T2DM group was significantly lower 
than Control group (p<O.OOI) (Table 4). 
Lipid levels of study subjects 
Mean (±SD) serum triglycerides (TG, mg/dl) of the control and T2DM subjects was 
134.1±60.2 and 197.4±84.0 respectively which showed statistical significant difference 
(p<O.OO I) (Table 5). 
Mean (±SD) serum total cholesterol (mgldl) of the control and T2DM subjects was 
I 92.4±60.2 and 229.0±50.8 respectively which showed significantly higher in the T2DM 
group compared to the controls (p<O.OOI) (Table 5). 
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Mean (±SD) high density lipoprotein cholesterol (l-IDL-c, mgldl) of the control and 
T2DM subjects was 34.6± 1 0.3 and 32.0±8.1 respectively which did not show significant 
difference (p=O.1 00) (Table 5). 
Mean (±SD) low density lipoprotein cholesterol (LDL-c, mgldl) of the control and 
T2DM subjects were 132.0±38.0 and 155.6±50.7 respectively which showed significant 
difference (p=0.003) (Table 5). 
Table 2: Age, BMl, b lood pressure, S Creatinine, SGPT level of the study subjects 
Vllriables 
Control T2DM lip values 
(n=9 1) (n=65) Control vs T2DM 
Age (yrs) 40.53±8.4 1 42.86±6.80 1.913/0.058 
BMI (kgll112) 25 .92±3.95 24.99±4.09 1.403/0.163 
SBP (l11ml-lg) 112.12± 12.25 122.53±14.50 4.157/<0.00 1 
DBP (l11l11Hg) 75 .00±7.93 77.90±8.76 2.091/0.093 
S Creatin ine (l11g1dl) 0.99±0.16 0.95±0.15 1.658/0.099 
SGPT (U/L) 26.39± 14.l2 29.39±28 .39 0.786/0.434 
Results were expressed as mean±SD. 
Statistical comparison between groups was performed using unpaired Student's 't' test. 
BM I, Body Mass Index; SBP, Systol ic Blood Pressure DBP, Diastolic Blood Pressure; S 
Creatinine, Serum Creatinine; SGPT, Serum Glutamic Pyruvic Transaminase; T2DM, Type 2 
Diabetes. 
50 
Table 3: Anthropometric measurements of the study subjects 
Variables 
Control T2DM lip values 
(n=9 1) . (n=65) Control vs T2DM 
MAC (cm) 29.83±4. 17 29.1 2±5.44 0.85 1/0.396 
T SF (nun) 23. 17± 13.05 19.55±9.66 1.867/0.064 
SSF (mm) 30.79±11 .0 1 32.70± 10.88 1.063/0.29 1 
BFM (%) 30.03±6.60 28.5 1±6.52 1.408/0.16 1 
WHR 0.92±0.06 0.94±0.06 1.746/0.083 
Results were expressed as mcan±SD. 
Statistica l comparison between groups was perfo rmed using unpaired Student 's ' t' test. 
MAC, Mid Arm Circumferences; TSF, Tri ceps Skin Fo ld ; SSF, Sub Scapular Skin fold; BFM, 
Body Fat Mass; WHR, Waist Hip Ratio; T2DM, Type 2 Diabetes Mellitus. 
Table 4: Glycemic and insulinemic status of the study subjects 
Control T2DM 
Variables (n=9 1) (n=65) 
lip values 
Control vs T2DM 
FSG (mmolll) 5.0 1±0. 57 7.97±3 .~3 
PPG (mmolll) 5.75± 1.l1 15.26±4.86 
Insulin (Il U/ml)" 10.55±5.3 1 17. 19± 10.87 4.068/<0.00 1 
HOMA % B" 11 5±52 100±57 1.363/0.176 
HOMA %S' 79.9±20.5 48.9±21.7 7.248/<0.00 I 
Results were expressed as mean±SD. 
Statistical comparison between groups was perfo rmed using unpaired Student' s ' I ' test. 
rSG, Fasting Serum Glucose; PPG, Postprand ial Glucose; HOMA%S, Insul in sensitivity 
assessed by Homeostatic Model Assessment; HOMA%B, B-cell function assessed by 
Homeostatic Model Assessment; T2DM, type 2 diabetes . 
" Was determined in 10 1 (42 Controls and 59 T2DM) subjects 
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Table 5: Lipid levels of the study subjects 
Variables 
Control T2DM lip values 
(n=91 ) (n=65) Control vs T2DM 
TG (mg/dl) 134.07±60.l6 197.38±84.04 5.107/<0.00 I 
T Chol (mg/dl) I 92.42±39.18 229.02±50.80 4.866/0.001 
HDL-c (mgldl) 34.62± 1O.25 32.02±8.13 1.65510.119 
LDL-c (mgldl) 131.98±37.90 155.54±50.70 3.043/0.027 
Results were expressed as mean±SD. 
Statistical comparison between groups was performed using unpaired Student's 't' test. 
TG, Triglycerides; T chol, total cholesterol; HDL-c, High-density lipoprotein cholesterol; LDL-c, 
Low density lipoprotein cholestero l, T2DM, type 2 diabetes mellitus. 
CANDIDATE GENE MARKER ANAL YSES 
CAPN 10 SNP-44 (T>C) genotype of the study subjects 
Genotype frequencies of the CAPN 10 gene SNP-44 (T>C) control variants were 0.670, 
0.297 and 0.330 for wild type, heterozygous (Ht) variant and homozygous (Hz) variant 
respectively. In the T2DM group the frequencies ' were 0.662, 0.323 and 0.150 
respectively. This genotype frequency distribution in the two groups did not show 
statistical significant association ci'=0.547;p=0.761) (Table 6). 
When heterozygous and homozygous variant genotypes were grouped together, the 
di stribution was as following: Control- 0.670, and 0.330 for wild and variant 
respectively; T2DM- 0.663 and 0.338 respectively. This distribution also did not show 
significant association (/=0.013; p=0.909) for the genotype frequencies (Table 7) . 
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Table 6: CAPN 10 SNP-44 (T>C) variant genotype of the study subjects 
CPN 10 (T>C) marker Control (11=91) T2D M (n=65) Total (n=156) Genotype 
Wild (T,T) 0.670 (61) 0.662 (43) 0.667 (104) 
HI varianl (T,C) 0.297 (27) 0.323 (21) 0.308 (48) 
Hz variant (C,C) 0.330 (3) 0.150(1) 0.260(4) 
/ =0.547 P=0.761 
Results were expressed as frequency (number) . 
Chi-square test was performed to calculate stati stical association. 
Hz Wild , homozygous wild ; Ht variant, heterozygous variant; Hz variant, homozygous 
variant; T2DM, IYpe 2 diabetes. 
Table 7: CAPN 10 SNP-44 genotype (Ht and Hz variant together) of the study 
subjects 
CI}N 10 SNP-44 (T>C) Control (n=9 1) T2DM (n=65) Tota l (n=156) 
Wild (C'C) 0.670(61) 0.663(43) 0.667(104) 
Variant 0.330(30) 0.338(22) 0.333(52) 
/=0.013 p=0.909 
Results were expressed as frequency (number). 
Chi-square test was performed to calcu late statistical association. 
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Glyccmic and insulincmic status of study subjccts on thc basis of CAPNIO SNP-44 
T>C variant 
Mean (±SO) fasting glucose levels in subjects with wild and variant (heterozygous and 
homozygous together) genotype was found to be almost similar in the control (S.O±O.6 
and 5.0±O.5 respectively; p=O.633) as well as in T20M subjects (7.4±3.2 and 9.2±4.7 
respectively; p=O.116) (Table 8). 
Mean (±SO) postprandial glucose levels in subjects with wild and variant (heterozygous 
and homozygous together) genotype was found to be almost similar in the control 
(S.7± 1.1 and 5.8±1.2 respectively; p=O.920) as well as in T20M subjects (14.7±4.S and 
l6.3±S.4 respectively; p=O.268) (Table 8). 
Mean (±SO) insulin levels in subjects with wild and variant (heterozygous and 
homozygous together) genotype was found to be almost similar in the control (9.8±2.S 
and l2.1 ±8.8 respectively; p=0.377) as well as III T20M subjects (18.6±12.3 and 
l3.7±4.9 respectively; p=O.114) (Table 8). 
Mean (±SO) HOMA%B in subjects with wild and variant (heterozygous and 
homozygous together) genotype was found to be almost similar in the control 
(I07.2±24.7 and l32.3±85.8 respectively; p=O.320) as well as in T20M subjects 
(I OS.6±S8.8 and 8S.S±S2.3 respectively; p=O.226) (Table 8). 
Mean (±SO) HOMA %S in subjects with wild and variant (heterozygous and 
homozygous together) genotype was found to be almost similar in the control (80.6± 18 .8 
and 78.2±24.6 respectively; p=O.72I) as well as in T20M subjects (47.3±21.6 and 
S2.8±21.9 respectively; p=O.388) (Table 8). 
BMI, WHR and Blood prcssure of study subjects on the basis of CAPNIO SNP-44 
T>C variant 
Mean (±SO) BMI in subjects with wild and variant (heterozygous and homozygous 
together) genotype was found to be almost similar in the control (25.8±4.2 and 26.1±3.4 
respectively; p=0.423) as well as in T20M subjects (24.8±3.9 and 2S.4±4.4 respectively; 
p=O.S60) (Table 9). 
Mean (±SO) waist to hip ratio in subjects with wild and variant (heterozygous and 
homozygous together) genotype was found to be almost similar in the control (O.92±O.OS 
and O.92±O.06 respectively; p=O.8S0 as well as in T20M subjects (O.93±O.OS and 
O.94±O.06 respectively; p=O.S39) (Table 9). 
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Mean (±SO) SBP in subjects with wild and variant (heterozygous and homozygous 
together) genotype was found to be almost similar in the control (l0.3±11.1 and 
110.3± 11.1 respecti ve ly; p=0.055) as well as 111 T20M subjects (121±15.1 and 
122.5± 13.5 respectively; p=0.691) (Table 9). 
Mcan (±SO) OBP in subjects with wild and variant (heterozygous and homozygous 
together) genotype was found to be almost similar in the control (73.7±7.3 and 73 .7±7.2 
respectively; p=0.037) as well as in T20M subjects (77.8±8.7 and 78.2±9. 1 respectively; 
p=0.G5G) (Table 9). 
Lipid levels of study subjects on the basis of CAPNIO SNP-44 T>C variant 
Mean (±SO) triglyceride in subjects with wild and variant (heterozygous and 
homozygous together) genotype was found to be almost similar in the control 
(13 1.8±G1.3 and 138.8±58 .6 respecti vely; p=0.599) as well as in T20M subjects 
(195 .9±82.7 and 200.6±88.9 respectively; p=O.842) (Table 10). 
Mean (±SO) total cholesterol in subjects with wild and variant (heterozygous and 
homozygous together) genotype was found to be almost similar in the control 
(196.0±42.3 and 197±38 respectively; p=0.894 as well as in T20M subjects (225.0±50.0 
and 185.1±3 1.3 respectively; p=0.393) (Table 10). 
Mean (±SO) l-lDL-c in subjects with wild and variant (heterozygous and homozygous 
together) genotype was fOllnd to be almost similar in the control (35.8±11.8 and 32.1 ±4.3 
respecti vely; p= 1.29) as well as in T20M subjects (3 1.4±9.27 and 33.3±5.1 respectively; 
p=0.292) (Table 10). 
Mean (±SO) LOL-c in subjects with wild and variant (heterozygous and homozygous 
together) genotype was fOllnd to be almost similar in the control (l33 .6±41.1 and 
128.4±30.0 respectively; p=0.565) as well as in T20M subjects (153.3±50.3 and 
I G0 .4±52. 7 respectivel y; p=0.G28) Crable 10). 
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Tablc 8: G lyccmic and insu lincmic status of thc study subjccts on thc basis of 
CAI'N 10 SNl'-44 T>C variant gcnotypc 
FSG ]'PG F Insulin 
HOMA% B* HOMA%S* (mmol/l) (mmol/l) (pmol / l)' 
COlltrol subjects 
Wild 5.0±0.6 5.7± 1.I 9.S±2.5 107.2±24.7 SO.6± IS .S (n=61) 
Variant 5.0±0.5 5.8± 1.2 12.I ±S.8 132.3±S5.8 78.2±24.6 (n=43) 
t/p val lies 0.479/0.633 0.10110.920 0.916/0.377 1.035/0.320 0.360/0.72 1 
T2DM subjects 
Wild 7.4±3.2 14.7±4.5 IS .6± 12.3 I05 .6±5S.S 47.3±21.6 (n=30) 
Variant 9.2±4.7 16.3±5.4 13 .7±4.9 85.5±52.3 52.8±21.9 (n=22) 
IIp values 1. 635/0.11 6 1.126/0.268 1.607/0.114 1.224/0.226 0.876/0.388 
Results were expressed as mean ± SD. 
Statistical comparison between groups was performed using unpaired Student' s ' t' test. 
Variant, heterozygous and homozygous variant together; FSG, fasting serum glucose; PPG, 
postprandial glucose; F insulin , Fasting Insulin; HOMA %B, Homeostasis mode l assessment B-
cell Function; HOM A %S, Homeostasis mode l assessment insulin sensitivity; T2DM, type 2 
diabetes. 
'Determined in 42 control (Wi ld vs Variant, 29 vs 13) and 59 T2DM (Wild vs Variant, 42 vs 17) 
subjects. 
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Table 9: BMI, WHR and blood pressure of the study subjects on the basis of 
CAPN 10 SNP-44 T>C variant genotype 
BMI SBP DBP 
COlltrol subjects 
Wild (n=61) 2S.8±4.2 0.92±0.OS I 13.3± 1 1.1 73.7±7.3 
Variant 26.1 ±3.4 0.92±0.06 I 10 .'3±1 1.1 74.7±7.2 (n=43) 
lip values 0.51210.423 0.19010.850 1.96410.065 2.14810.067 
T2DM subjects 
Wild (n=30) 24.8±3.9 0.93±0.OS 121 ± IS.1 77 .8±8.7 
Variant 2S.4±4.4 0.94±0.06 122.S±13.S 78.2±9. 1 (n=22) 
lip values 0.50210.560 0.61910.539 0.40010. 691 0.18210.656 
Results were expressed as mean ± SO. 
Stati stica l comparison between groups was performed using unpaired Student' s 't ' test. 
Variant, heterozygous and homozygous variant together; BMI, Body Mass Index; SBP, Systolic 
Blood Pressure DBP, Diasto lic Blood Pressure; T2DM, Type 2 Diabetes. 
57 
Table 10: Lipid levels of the study subjects on the basis of CAPN 10 SNP-44 T>C 
variant genotype 
TG Cholesterol HDlrC LDirc 
COl/trol slIbjects 
Wild (0=6 1) 131.8±6 1.3 I 96.0±42.3 . 35.8±11.8 I 33.6±4 I. I 
Variant 138.8±58.6 185. 1±3 1.3 32. 1±4.3 128.4±30.0 (n=43) 
IIp values 0.529/0.599 / .253/0.2/3 1.534/ 1.29 0.587/0.565 
T2DM sllbjects 
Wild (n=30) I 95 .9±82.7 225.0±50.0 31.4±9.27 I 53.3±50.3 
Variant 200.6±88.9 236.7±56.8 33.3±5. 1 160.4±52.7 (n=22) 
tIp values 0.201/0.842 0.863/0.393 1.06310.292 0.49010.628 
Results were expressed as mean ± SO. 
Stat istical comparison between groups was perfo rmed usi ng unpaired Student's ' t' test. 
Variant, heterozygous and homozygous variant together; TG, Triglycerides; T chol, total 
cholesterol; HDL-c, High-density lipoprotein cholesterol; LDL-c, Low density lipoprotein 
cholesterol , T2DM, type 2 diabetes. 
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Chapter 5 
DISCUSSION 
DISCUSSION 
Insulin resistance and/or progressive B cell dysfunction have been implicated in the 
pathogenesis of type 2 diabetes (Khan 1992). However, the specific molecular defects 
affecting insulin sensitivity and/or B cell secretory dysfunction still remained to be 
clearly understood. 
Prevalence of T2DM found to vary mostly around 10-15% in different populations. 
However, in certain ethnic groups' prevalence of diabetes found to be very high (Lillioja 
et al., 1991). Moreover high concordance for diabetes (63-90%) was observed in 
monozygotic twin pairs, which have strongly suggested a heritable genetic component 
creates susceptibility for the development ofTIDM. 
Relentless search continued for diabetogenic gene(s) by different research groups. 
Linkage analyses showed some breakthrough in this regard, which has identified several 
specific gene loci in a few number of families. Diabetes found to follow autosomal 
dominant Mendelian pattern of inheritance. These groups of patients are relatively 
young, normal to moderate obese, who are termed as maturity onset of the diabetes 
young (MODY) which accounts for 10% of all TIDM patients in the world. However 
genetic determinants for majority of the late onset TIDM remain to be elusive. 
For sometimes researchers have started genome wide scan in search of different disease 
related genes. Some of the groups have completed first stage of genome scan. The first 
gene discovery from genome wide scan was identification of calpain 10 gene in Mexican 
American TIDM patients. Calpain 10 was found to be account for 14% of the population 
attributed risk for TIDM (Horikawa et. al., 2000). Later on the CAPN I 0 gene 
polymorph isms were investigated in different other populations of European origin for 
its role in the development of TIDM (Evans et al., 200 I). However, these studies have 
failed to replicate the association at the CAPN I 0 polymorphic allele (Horikawa et al., 
2000), but suggested that other alleles at this locus may increase the risk for TIDM in the 
UK population. 
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Single nucleotide polymorphism (SNI"s) in the CAI'NIO gene was found not to be 
associated in the Finish cohort (Fingerlin el ai., 2002). However, Rasmussen et al (2002) 
have shown that different haplotypes of CAPN 10 gene variants confer low risk for 
T20M in Scandinavian population. Earlier Song et al (2004) suggested that both large-
scale and well-designed association studies are needed to explain the findings regarding 
the role of CAI'N 10 gene polymorphism and the pathogenesis of T20M. Functional 
studies have been suggested to reliably con finn or conclusively refute the initial 
hypothesis regarding the role of CAPN 10 in T20M risk in the' Europoid population 
(Einarsdottir el. al., 2006). 
The candidate CAPN 10 gene polymorphisms were also investigated in different Asian 
populations. Of these most notable ones are carried out by Cassell et al (2002) in South 
Indian and Kang et al (2006) in Korean ethnic population. Cassell et al (2002) in their 
study identified a particular haplotype conferring increas~d risk for both IFG/IGT and 
type 2 diabetes mellitus. However owing to the relative infrequency of at risk 
combination in the studied subjects they have suggested that CAPN I 0 gene was not a 
common detenninant at susceptibility to T20M. 
In the present study T20M subjects found to have significantly low insulin sensitivity 
(48.9±21.7), as evaluated by HOMA%S, compared to the BMI matched controls (Table 
5). However, the lower insulin sensitivity was found to be consistent with lower value 
(67.6±1.7) and (57.7±16.8) by Roy et al (2007) and Rahman (2008) respectively. This 
lower HOMA%S value in this subset of T20M subjects further strengthen the notion of 
both insulin secretory dysfunction and lower insulin sensitivity are involved in the 
pathogenesis ofT20M in Bangladesh population. 
Risk factors for T20M like BMI and WHR between the T20M and control- group did 
not show statistical difference. This feature was also in common with the previous 
studies. Variations in Calpain 10 gene have shown to affect blood glucose levels in 
British population. This effect has been attributed, at least partly, to its effect on the early 
insulin secretory response (Lynn el al., 2002). A positive effect of haplotypic 
combination was also shown by Cassell et al (2002) on South Indian popUlation. 
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Since both secretory defect and tendency to insulin resistance were observed in T20M 
patients of Bangladesh, attempts were made to explore its pathological basis. As a part of 
ongoing research activities to investigate the molecular basis of pathogenesis at T20M 
subjects, the present study was undertaken to determine insulin secretory capacity and 
sensitivity and their relationship with CAPN 10 gene SNp·44 T>C genotype frequencies. 
The genotype frequency did not show significant association with T20M. This finding of 
the present study was in agreement with the study ofOrho·Melander et al (2002). Studies 
involving determination of CAPN 10 gene SNP -44 T>C genotype was however rare. In 
most of the cases the marker was analyzed with other polymorphism. In the present study 
the determination of the marker was confined to only SNp·44 T>C. 
CAPN 10 gene SNp·63 C>T and In/Del 19 polymorphisms were also determined which 
did not show significant association with T20M of Bangladeshi origin (Sultana 2009). 
The findings strongly suggest that CAPN 10 gene common polymorphism may not be 
causally associated with T20M in this population. 
Although, it is consistent with finding of Roy et al (2007) who found predominant 
insulin secretory defect. In the present study individuals possessing variant genotypes in 
either T2DM or control group did not show any statistical difference. Waist to hip ratio 
has recently been considered as important indicator of diabetes associated risk. In this 
subset of T20M subjects WHR did not show significant difference compared to the age· 
and BMI·match control. 
Conclusions 
The present data concluded that: (i) CAPN 10 SNP 44 T>C polymorphism was not 
associated with T20M of Bangladeshi origin. (ii) Insulin sensitivity appeared to be 
predominant in the subsets of T20M subjects, and (iii) CAPN 10 SNP 44 T>C variant 
did not show any insulin sensitivity ofthe study subjects. 
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Limitations of the study 
I. Number ofT2DM subjects in the study is small; ' 
II . For this particular study on ly one polymorphic marker was determined. 
Recommendations 
I. Study involving larger number of samples to achieve the statistical power for 
analysis, and 
II. Inclusion of other polymorphic markers is recommended to conc lusively 
comment on the effect of eAPN 10 gene variants in the pathogenesis of T2DM 
of Bangladesh i origin. 
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APPENDICES 
Appcndix I 
Data Collection Sheet 
MS Thesis 
1. Identification No: 
2. Particulars of the Subjects: 
i) Name: 
-----------------------------
ii) Father's IHusband 's Name: _____________ _ 
iii) Age: years 
---------
iv) Sex: Male I Female 
v) Address: 
Present: ____________________ _ 
Permanent: ___________________ _ 
vi) Phone/Cell: _________________ _ 
vii) Date o f I SI Examination: _____________ _ 
3. Past Mcdical history: 
4. Drug histoJ"), : 
Anti-HTN: 
Lipid Lowering: 
Anti-obesity: 
Anti-i schemic: 
73 
5. Family history : 
i) Family hi story of Diabetes 
ii) Family history of HTN 
6. Socia l h istory : 
i) Madlal slalus: Married / Unmarried / Widow. 
ii) Scio-economics SIal us: 
Tota l members of the fa mily: 
Income of the family (Month ly / Yearly): 
iii) Educational S tatus : 
C lass I-VIII / SSC-HSC / Grad uate / Others (L _ ____ -') 
iv) Occu pa tion: 
Current Des ignatio n Duration: 
Type of Work 
Professiona l / Housewife / Sa les Person / Domestic help / 
Laborer / Others ( ) 
v) Habit: 
Exercise: 
Present (Type , Duration 
Past (Type , Duration 
Not 
Smoking: 
Present (Duralion , Sticks/day 
Past (Duration , Sticks/day 
Not 
Betel Leaf: Yes / No ( ) 
) 
) 
) 
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7. I)hysical Examination: 
(b) Anthropometry: 
(ii) I-Ieight in meter: 
(iii) Weight in Kg: 
(iv) Waist circumference: 
(v) Hip circumference: 
(v i) Mid-upper arm circumference (MUPC): 
(vii) Sk in fo ld th ickness: 
Triceps: 
Sub-scapu lar skin fold s thickness : 
(viii) Body fat mass : 
(b) Blood pressure: 
151 reading 2"" reading Average reading 
Systo lic 
Diasto lic 
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